Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),Cell Line Sex - Both (118),Cell Line Sex - Male (64),Cell Line Sex - Female (40),Cell Line Ancestry - Caucasian (41),Cell Line Ancestry - Asian (28),Disease Modelling - Genetic Disorders (18),Disease Modelling - Arrhythmic (15),Disease Modelling - Ischemic Infarction (9),Disease Modelling - Dilated Cardiomyopathy (6),Disease Modelling - Hypertrophic Cardiomyopathy (6),Disease Modelling - Fibrotic (4),Pharmacological Intervention - Adrenaline (83),Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73),Pharmacological Intervention - Isoproterenol (71),Pharmacological Intervention - QT-Prolonging Drugs (36),Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),Pharmacological Intervention - Verapamil (27),Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),Pharmacological Intervention - E4031 (22),Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),Pharmacological Intervention - Traditional Chemotherapy Agents (18),Pharmacological Intervention - Doxorubicin (17),Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),Pharmacological Intervention - Other Antiarrhythmic Agents (13),Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),Pharmacological Intervention - Epinephrine (11),Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),Pharmacological Intervention - Class Ic Antiarrhythmics (Na+ Channel Blockers - Strong Blockade) (9),Pharmacological Intervention - Positive Inotropes (9),Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),Pharmacological Intervention - Cisapride (8),Pharmacological Intervention - Ranolazine (7),Pharmacological Intervention - Lidocaine (7),Pharmacological Intervention - Carbamylcholine (6),Pharmacological Intervention - Propranolol (5),Pharmacological Intervention - Blebbistatin (5),Pharmacological Intervention - Metoprolol (5),Pharmacological Intervention - Caffeine (4),Pharmacological Intervention - Carbenoxolone (4)
"['Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10)', 'Metabolic Component Category - Signaling Pathway Regulators (6)', 'T-tubule Structure (Found) Quantiles - Q1 (Yes) (18)', 'Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8)', 'Electrophysiology Analysis Method - Patch Clamp (59)', 'Metabolic Analysis Method - Seahorse (35)', 'Journal - Tissue Eng Part C Methods (6)', 'Electron Imaging - Transmission (62)', 'MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4)', 'hiPSC-CM Media Supplement - Rare (5)', 'Journal - Biosens Bioelectron (4)', 'Wnt Inhibitor - IWP (112)', 'hiPSC-CM Maturation Media - DMEM (35)', 'Insulin Start Day - 6 (20)', 'Cell Line - Cellapy (4)', 'hiPSC Backbone Media - Rare (19)', 'Seeding Confluency 3D (%) - 85 to 89 (12)', 'Wnt Induction - Rare (4)', 'Metabolic Component - Palmitic Acid (11)', 'Coating for Replating - Geltrex (10)', 'Publication Year - 2019 (57)', 'Metabolic Component Category - Kinase Inhibitors (3)', 'Insulin Withdrawal Duration (days) - 6 days (3)', 'Pharmacological Intervention - Caffeine (4)', 'Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6)', 'Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4)', 'hiPSC-CM Purification Duration (days) - 6 days (10)', 'Publication Year - 2021 (43)', 'Calcium Handling Analysis Method - Visual (104)', 'hiPSC-CM Media Supplement - GlutaMax (8)', 'Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8)', '3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47)', 'Pharmacological Intervention - Blebbistatin (5)', 'Insulin Start Day - 3 (5)', 'TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4)']","['Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10)', 'Number of Cell Lines - 2 (50)', 'Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7)', 'Differentiation Purity (%) Quantiles - Q1 (>95 and ≤99) (22)', 'Coating for Replating - Rare (6)', 'TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4)', 'Journal - Acta Biomater (10)', 'Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12)', 'Differentiation Purity Assessment - Flow Cytometry cTnT+ (135)', 'Gene Analysis Method - RNA (169)', 'Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5)', 'Disease Modelling - Hypertrophic Cardiomyopathy (6)', 'Deduced Culture Strategy - 2D Only (183)', 'Cell Line - Cellapy (4)', 'Wnt Induction Duration (days) - 3 days (38)', 'Journal - Rare (104)', 'Seeding Confluency 2D (%) - 80 to 84 (5)', '2D Surface - Micropatterned (27)', '2D Surface - Microparticle/fluid (3)', 'Metabolic Component - Insulin-Transferrin-Selenium (3)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11)', 'hiPSC-CM Media Supplement - Rare (5)', '2D Surface - Nanotopography (6)', 'Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13)', 'Contractile Analysis Method - Rare (7)', 'MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4)', 'Seeding Confluency (%) - 80 to 84 (12)', 'hiPSC Matrix Coating - EBs (18)', 'Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108)']","['Cell Line - BJ1 (7)', 'Contractile Analysis Method - Force Transducer (27)', '3D Tissue Media - Iscove (5)', 'Journal - Circulation (11)', 'Maturation Strategy - Tension (64)', '3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11)', 'Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10)', '3D Platform - Collagen (38)', 'Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7)', '3D Tissue Media - Growth Factor (12)', 'hiPSC Backbone Media - DMEM (10)', 'hiPSC Backbone Media - Conditioned (12)', '3D Stromal Cell Source - Human Fibroblast (38)', 'Insulin Start Day - 11 (3)', 'hiPSC-CM Purification Duration (days) - <3 days (31)', 'Wnt Inhibitor - IWP (112)', 'Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9)', 'Pharmacological Intervention - T3 (3)', 'Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14)', '3D Estimated Cell Density (mil cells/mL) Quantiles - Q3 (>5 and ≤10) (30)', 'Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8)', 'Cell Coculture - Cardiomyocyte (157)', 'Publication Year - 2014 (3)', '3D Stromal Cell Source - hiPSC-SmoothMC (3)', 'Disease Modelling - Genetic Disorders (18)', 'Number of Cell Lines - 3 (29)', 'Disease Modelling - Hypertrophic Cardiomyopathy (6)', 'Electron Imaging - Transmission (62)', 'Day of Insulin Addition - not 9 (3)', 'Day of Insulin Addition - not 18 (10)']","['Contractile Analysis Method - Force Transducer (27)', 'Differentiation Purity (%) Quantiles - Q2 (>90 and ≤95) (27)', 'Cell Line - BJ1 (7)', 'Purification Protocol - Glucose and Lactate (85)', 'Day of Insulin Addition - not 24 (9)', 'Day of Insulin Addition - not 23 (10)', '2D Surface - Hydrogel (17)', 'Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10)', 'Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7)', 'Day of Insulin Addition - not 22 (12)', 'Seeding Confluency 3D (%) - 95 to 100 (13)', 'Journal - Circulation (11)', 'Wnt Inhibitor - IWP (112)', 'Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73)', 'Number of Cell Lines - 2 (50)', 'Pharmacological Intervention - Isoproterenol (71)', 'Maturation Strategy - Tension (64)', 'Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30)', '3D Estimated Tissue Size (mm2) Quantiles - Q4 (>0.13 and ≤2) (31)', '3D Tissue Media - High-glucose DMEM (9)', 'hiPSC-CM Purification Duration (days) - 7 days (6)', 'Pharmacological Intervention - Adrenaline (83)', 'hiPSC Backbone Media - Embryonic Stem Cell (127)', 'Electrophysiology Analysis Method - Optical Mapping (39)', 'hiPSC Backbone Media - StemFlex (5)', 'Cell Line - Cor.4U (16)', 'Publication Year - 2017 (43)', 'Day of Insulin Addition - not 21 (14)', 'Day of Insulin Addition - not 20 (15)', 'hiPSC-CM Backbone Media - DMEM (18)', 'Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10)', 'Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11)', 'Differentiation Purity Assessment - Visual Inspection (6)', 'hiPSC-CM Maturation Media - Cor.4U Complete (6)']","['Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13)', 'Contractile Analysis Method - Deflection (39)', 'Metabolic Component - Palmitic Acid (11)', 'Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9)', 'Differentiation Purity Assessment - Flow Cytometry cTnT+ (135)', 'Cell Line Ancestry - Asian (28)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11)', 'Metabolic Component - Fatty Acid (13)', '3D Stromal Cell Source - Mesenchymal Stem Cell (12)', '3D CM Ratio (CM-EC-SC) Quantiles - Q2 (>75 and ≤91) (28)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10)', 'Journal - Tissue Eng Part C Methods (6)', 'Differentiation Purity (%) Quantiles - Q5 (>30 and ≤79) (32)', 'Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9)', 'hiPSC-CM Media Supplement - Rare (5)', 'Cell Line - BJ RiPS (4)', '3D Tissue Media - RPMI-1640 (72)', 'Cell Line Sex - Male (64)', 'Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11)', 'Electron Imaging - Transmission (62)', '3D Stromal Cell Source - Cardiac Fibroblast (32)', 'Journal - Sci Transl Med (3)', 'Wnt Inhibitor - Wnt-C59 (30)', 'Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8)', 'hiPSC-CM Purification Duration (days) - >9 days (5)', 'Journal - ACS Biomater Sci Eng (3)', 'Journal - Acta Biomater (10)', '3D Estimated Tissue Size (mm2) Quantiles - Q2 (>9.12 and ≤26.2) (26)', 'Fatty Acid Metabolism Assessed - Yes (20)']","['Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8)', 'Calcium Handling Analysis Method - Visual (104)', 'Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7)', 'Journal - Cell Stem Cell (6)', 'Gene Analysis Method - Rare (5)', 'Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34)', 'Metabolic Component - Palmitic Acid (11)', 'hiPSC-CM Purification Duration (days) - >9 days (5)', 'Metabolic Component Category - Sugars and Carbohydrates (9)', 'Metabolic Analysis Method - Seahorse (35)', 'Purification Protocol - Glucose and Lactate (85)', 'Metabolic Component Category - Fatty Acids and Lipids (21)', 'Metabolic Component - Fatty Acid (13)', 'Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9)', 'Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5)', 'Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8)', 'Publication Year - Late-2010s (196)', 'Insulin Start Day - 1 (19)', 'Publication Year - 2015 (19)', 'hiPSC-CM Purification Duration (days) Quantiles - Q1 (>4 and ≤20) (31)', 'Journal - Circ Res (5)', 'Differentiation Purity Assessment - Flow Cytometry cTnI+ (3)', '3D Platform - Matrigel (33)', 'Journal - Stem Cells (11)', 'Publication Year - 2017 (43)', 'Metabolic Component Category - Metabolic Modulation (20)', 'Insulin Start Day - 11 (3)', 'Disease Modelling - Dilated Cardiomyopathy (6)']","['Pharmacological Intervention - Isoproterenol (71)', 'Journal - Cell Stem Cell (6)', 'hiPSC Matrix Coating - Rare (8)', 'Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73)', 'Purification Protocol - Metabolic (8)', 'Pharmacological Intervention - Adrenaline (83)', 'Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14)', 'Cell Line - 253G1 (10)', 'hiPSC-CM Purification Duration (days) - 3 days (13)', 'Publication Year - 2024 (7)', '3D Platform - Fibronectin (3)', '3D Tissue Media - MEM-α (60)', 'Disease Modelling - Dilated Cardiomyopathy (6)', 'Pharmacological Intervention - Carbamylcholine (6)', '3D Platform - Extracellular Scaffold (18)', 'Insulin Start Day - 8 (15)', 'Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8)', 'Pharmacological Intervention - Propranolol (5)', 'Insulin Withdrawal Duration (days) - 3 days (6)', 'Contractile Analysis Method - Deflection (39)', 'Journal - Stem Cell Res Ther (3)', 'Cell Line - Cor.4U (16)', 'Metabolic Analysis Method - Genetic (3)', '3D Tissue Media - Rare (13)', 'Cell Line - SCVI-273 (8)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10)', 'Pharmacological Intervention - Traditional Chemotherapy Agents (18)', 'Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8)', '2D Surface - Microelectrode Array (9)', 'Pharmacological Intervention - Other Antiarrhythmic Agents (13)', 'hiPSC-CM Media Supplement - VEGF (4)', 'hiPSC Matrix Coating - Vitronectin (10)', 'Electrophysiology Analysis Method - Motion-Contrast Reconstruction (5)', 'Differentiation Purity Assessment - Visual Inspection (6)', 'Journal - Biomaterials (16)', 'Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11)']","['Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10)', 'Seeding Confluency (%) - 80 to 84 (12)', 'Calcium Handling Analysis Method - Visual (104)', 'Seeding Confluency 2D (%) - 80 to 84 (5)', 'Journal - Nano Lett (3)', 'hiPSC Matrix Coating - Geltrex (33)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10)', 'Publication Year - 2015 (19)', 'Maturation Strategy - ECM (21)', 'Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8)', 'Journal - Stem Cells (11)', 'Journal - PLoS One (9)', 'Coating for Replating - Fibronectin (32)', 'hiPSC Backbone Media - mTeSR (106)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10)', '2D Surface - Hydrogel (17)', 'Sacromere or Cellular Alignment Analysis - Yes (72)', 'Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10)', 'Coating for Replating - Matrigel (65)', 'Differentiation Purity Assessment - Flow Cytometry VCAM1+ (4)', 'Seeding Confluency 2D (%) - 70 to 79 (6)', 'Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10)', 'Wnt Inhibitor - IWR (56)', 'Insulin Start Day - 6 (20)', 'Differentiation Purity Assessment - Flow Cytometry SIRPA+ (4)', 'Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11)', 'Seeding Confluency (%) - 70 to 79 (11)', 'Seeding Confluency 3D (%) - 80 to 84 (5)', 'Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10)', 'Gene Analysis Method - RNA (169)', 'Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34)', 'hiPSC-CM Media Supplement - Mercaptoethanol (10)', 'Journal - J Mol Cell Card (6)', 'Cell Line - ATCC (5)']","['Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11)', 'Publication Year - 2017 (43)', 'Coating for Replating - Gelatin (43)', 'Journal - PNAS (3)', 'Calcium Handling Analysis Method - Visual (104)', 'Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13)', 'Day of Insulin Addition - not 11 (5)', 'Differentiation Purity Assessment - IHC cTnT (7)', 'Insulin Start Day - 0 (7)', 'Seeding Confluency 3D (%) - 90 to 94 (13)', 'hiPSC Backbone Media - DMEM (10)', 'hiPSC Matrix Coating - MEF feeder cells (8)', 'hiPSC-CM Media Supplement - Nonessential Amino Acids (8)', 'Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8)', 'Cell Line Ancestry - Caucasian (41)', 'hiPSC-CM Media Supplement - GlutaMax (8)', 'Journal - Biomater Sci (7)', '3D Tissue Media - Growth Factor (12)', 'hiPSC-CM Media Supplement - FBS (16)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10)', 'hiPSC-CM Purification Duration (days) - 3 days (13)', 'Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9)', 'Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10)', 'Journal - Biomaterials (16)', 'Cell Line Sex - Both (118)']","['Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13)', 'Disease Modelling - Genetic Disorders (18)', 'Disease Modelling - Arrhythmic (15)', 'Coating for Replating - Fibronectin (32)', 'Journal - Biosens Bioelectron (4)', 'Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6)', 'Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10)', 'Publication Year - 2016 (32)', 'Cell Line - BJ RiPS (4)', 'Journal - Circ Res (5)', 'Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6)', 'Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11)', 'Differentiation Purity (%) Quantiles - Q4 (>79 and ≤85) (40)', 'Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10)', 'Insulin Start Day - 3 (5)', 'Journal - Acta Biomater (10)', 'Wnt Inhibitor Duration (days) - 3 days (17)', 'Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12)', 'Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108)', 'Differentiation Purity Assessment - Flow Cytometry a-actinin+ (9)', 'Calcium Handling Analysis Method - Visual (104)', 'Cell Line - iCell (47)', '2D Surface - ECM-coated (115)', 'Coating for Replating - Laminin (5)', 'Pharmacological Intervention - Propranolol (5)', 'Electrophysiology Analysis Method - Patch Clamp (59)']","['Pharmacological Intervention - Cisapride (8)', 'Publication Year - 2021 (43)', 'Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12)', 'Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10)', 'Maturation Strategy - ECM (21)', 'Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10)', 'hiPSC-CM Media Supplement - L-glutamine (19)', 'Sacromere or Cellular Alignment Analysis - Yes (72)', 'Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30)', 'Electrophysiology Analysis Method - Optical Mapping (39)', 'Pharmacological Intervention - Cardioselective Ca Channel Blockers (31)', 'Wnt Induction - Rare (4)', 'Pharmacological Intervention - QT-Prolonging Drugs (36)', 'Metabolic Component - Rare (4)', 'Differentiation Purity (%) Quantiles - Q1 (>95 and ≤99) (22)', 'Contractile Analysis Method - Deflection (39)', 'hiPSC-CM Media Supplement - VEGF (4)', 'Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13)', 'Number of Cell Lines - 3 (29)', 'Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13)', 'Pharmacological Intervention - Metoprolol (5)', 'Number of Cell Lines - >5 (9)', 'Journal - Front Cell Dev Biol (3)', '2D Surface - Hydrogel (17)', 'Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22)']","['Electrophysiology Analysis Method - Patch Clamp (59)', 'Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13)', 'Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12)', 'Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11)', 'Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9)', 'Differentiation Purity (%) Quantiles - Q1 (>95 and ≤99) (22)', 'Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5)', 'Electron Imaging - Transmission (62)', 'T-tubule Structure (Found) Quantiles - Q1 (Yes) (18)', 'Coating for Replating - Synthemax (3)', 'Metabolic Analysis Method - Seahorse (35)', 'Number of Cell Lines - 3 (29)', '2D Surface - Nanotopography (6)', 'Metabolic Component Category - Signaling Pathway Regulators (6)', 'Seeding Confluency (%) - Rare (43)', 'hiPSC-CM Maturation Media - Commercial Kit (27)', 'Contractile Analysis Method - Traction Force Microscopy (9)', 'hiPSC-CM Media Supplement - L-glutamine (19)', 'Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8)', 'Metabolic Component Category - Kinase Inhibitors (3)', 'Seeding Confluency 2D (%) - Rare (13)', 'Maturation Strategy - Elastomeric (33)', 'hiPSC-CM Maturation Media - RPMI-1640 (153)', 'Publication Year - 2022 (20)']","['Electrophysiology Analysis Method - Patch Clamp (59)', 'Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10)', 'Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11)', 'Coating for Replating - Rare (6)', 'Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10)', 'Number of Cell Lines - 3 (29)', 'Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7)', 'Journal - Rare (104)', 'hiPSC-CM Media Supplement - Polyvinylalchohol (6)', '2D Surface - ECM-coated (115)', 'Wnt Induction - Rare (4)', 'hiPSC-CM Backbone Media - Commercial CM Kit (12)', 'Sacromere or Cellular Alignment Analysis - Yes (72)', 'Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10)', 'Cell Line - C25 (6)', 'hiPSC Backbone Media - Rare (19)', 'Metabolic Component - Lactate (4)', 'Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5)', 'Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8)', 'Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10)', 'hiPSC-CM Media Supplement - Lipids (9)', 'Cell Line - BJ1 (7)', 'Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10)', 'Pharmacological Intervention - Adrenaline (83)', '2D Surface - Nanotopography (6)', 'Purification Protocol - Metabolic (8)']","['Wnt Induction - Wnt3a (3)', 'Cell Line - 201B6 (3)', '3D Stromal Cell Source - hiPSC-MuralC (3)', 'Maturation Strategy - Other Cells (80)', 'hiPSC Backbone Media - Conditioned (12)', 'Maturation Strategy - Tension (64)', 'Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9)', 'Electrophysiology Analysis Method - Motion-Contrast Reconstruction (5)', 'New Media for Maturation - RPMI-1640 (30)', '3D Platform - Collagen (38)', '3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48)', 'Sacromere or Cellular Alignment Analysis - Yes (72)', '3D Platform - Matrigel (33)', '3D Endothelial Cell Source - hiPSC-EndothelialC (16)', 'Seeding Confluency 3D (%) - 95 to 100 (13)', 'Journal - Cell Stem Cell (6)', 'Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9)', 'Maturation Strategy - Electrical (39)', '3D Stromal Cell Source - Rare (4)', '3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47)', 'Electrophysiology Analysis Method - Patch Clamp (59)', '3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28)', '3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31)', 'Insulin Start Day - 5 (14)', '3D Stromal Cell Source - Dermal Fibroblast (7)', 'Journal - J Mol Cell Card (6)', 'Metabolic Component - IGF-1 (3)', 'Wnt Inhibitor - VEGF (3)', 'Cell Coculture - Endothelial Cell (35)', 'Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10)', 'Metabolic Component - Dexamethasone (7)', 'Cell Line - BJ1 (7)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10)', 'Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10)', 'Wnt Inhibitor - Rare (3)']","['TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4)', 'MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4)', 'MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4)', 'Contractile Analysis Method - Rare (7)', 'Journal - Stem Cell Reports (23)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11)', 'Disease Modelling - Arrhythmic (15)', 'Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10)', 'TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4)', 'Publication Year - 2019 (57)', 'Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9)', 'Disease Modelling - Genetic Disorders (18)', 'Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12)', '3D Platform - Extracellular Scaffold (18)', 'hiPSC-CM Purification Duration (days) - 4 days (29)', '2D Surface - Micropatterned (27)', 'Maturation Strategy - Tension (64)', 'Seeding Confluency 2D (%) - 70 to 79 (6)', 'Metabolic Component - B27 (3)']","['MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4)', 'MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4)', 'TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4)', 'Journal - Stem Cell Reports (23)', 'TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4)', 'Number of Cell Lines - 3 (29)', 'hiPSC-CM Media Supplement - Rare (5)', 'Calcium Handling Analysis Method - Visual (104)', 'Calcium Handling Analysis Method - Rare (4)', 'Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13)', 'hiPSC-CM Purification Duration (days) - 4 days (29)', 'Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14)', 'Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10)', 'Maturation Strategy - Elastomeric (33)', 'Pharmacological Intervention - T3 (3)', 'Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11)', 'Maturation Strategy - ECM (21)', 'Publication Year - 2019 (57)', 'Publication Year - 2022 (20)', 'Metabolic Component Category - Kinase Inhibitors (3)']","['MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4)', 'MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4)', 'Journal - Stem Cell Reports (23)', 'MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4)', 'Journal - Tissue Eng Part A (4)', 'MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4)', 'Insulin Withdrawal Duration (days) Quantiles - Q2 (>2 and ≤4) (25)', 'Insulin Withdrawal Duration (days) - 4 days (18)', '3D Stromal Cell Source - Cardiac Fibroblast (32)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10)', 'Journal - Nat Biomed Eng (5)', 'Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9)', 'Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14)', '3D Stromal Cell Source - Human Fibroblast (38)', 'hiPSC-CM Purification Duration (days) - 3 days (13)', '3D Stromal Cell Source - Dermal Fibroblast (7)', 'Calcium Handling Analysis Method - Visual (104)', 'Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11)', 'Publication Year - 2019 (57)', '3D Estimated Cell Density (mil cells/mL) Quantiles - Q3 (>5 and ≤10) (30)', '3D Tissue Media - RPMI-1640 (72)', 'Maturation Strategy - Elastomeric (33)', '3D Stromal Cell Source - hiPSC-CardiacF (8)', 'Journal - ACS Biomater Sci Eng (3)']","['Electron Imaging - Transmission (62)', 'Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13)', 'Differentiation Purity Assessment - Flow Cytometry cTnT+ (135)', 'Disease Modelling - Hypertrophic Cardiomyopathy (6)', 'Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10)', 'Pharmacological Intervention - Caffeine (4)', 'Gene Analysis Method - RNA (169)', 'Metabolic Component - Dexamethasone (7)', 'Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14)', 'Differentiation Purity (%) Quantiles - Q1 (>95 and ≤99) (22)', 'Number of Cell Lines - 2 (50)', 'Cell Line Sex - Female (40)', 'Seeding Confluency (%) - 95 to 100 (23)', 'Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13)', 'hiPSC-CM Purification Duration (days) Quantiles - Q1 (>4 and ≤20) (31)', 'Wnt Inhibitor Duration (days) - 4 days (19)', 'Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6)', 'hiPSC Matrix Coating - EBs (18)', '3D Stromal Cell Source - hiPSC-CardiacF (8)', 'Pharmacological Intervention - Doxorubicin (17)', 'Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8)', 'Calcium Handling Analysis Method - Visual (104)', 'Cell Line - 201B7 (9)', 'Seeding Confluency 2D (%) - 70 to 79 (6)', 'Publication Year - 2016 (32)', 'Pharmacological Intervention - Verapamil (27)', 'Cell Line - ATCC (5)', 'Wnt Inhibitor Duration (days) - 3 days (17)', 'Metabolic Analysis Method - Seahorse (35)', 'Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11)']","['3D Platform - Collagen (38)', 'Contractile Analysis Method - Deflection (39)', '3D Estimated Tissue Size (mm2) Quantiles - Q4 (>0.13 and ≤2) (31)', 'Cell Coculture - Cardiomyocyte (157)', '3D CM Ratio (CM-EC-SC) Quantiles - Q2 (>75 and ≤91) (28)', 'Deduced Culture Strategy - 3D Only (157)', '3D Stromal Cell Source - Human Fibroblast (38)', '3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119)', 'Cell Coculture - Stromal Cell (78)', 'Cell Line - BJ1 (7)', '3D Platform - Fibrin (50)', 'Insulin Start Day - 1 (19)', 'Journal - Biomaterials (16)', 'Maturation Strategy - Other Cells (80)', 'Seeding Confluency 3D (%) - 90 to 94 (13)', '3D Stromal Cell Source - Cardiac Fibroblast (32)', '3D SC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤10) (29)', 'Pharmacological Intervention - Carbenoxolone (4)', 'Seeding Confluency 3D (%) - 85 to 89 (12)', 'Pharmacological Intervention - Cisapride (8)', '3D Platform - Polyethylene Glycol (8)', '3D Platform - Extracellular Scaffold (18)', 'Maturation Strategy - ECM (21)', 'Seeding Confluency (%) - 90 to 94 (26)', 'Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5)', 'Maturation Strategy - Electrical (39)', 'Maturation Strategy - Mechanical (36)', 'Maturation Strategy - Tension (64)', '3D Tissue Media - High-glucose DMEM (9)', 'Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6)', 'Insulin Start Day - After 11 (7)', '3D Tissue Media - Iscove (5)', 'Disease Modelling - Fibrotic (4)', 'Publication Year - 2020 (51)', '3D Tissue Media - Rare (13)', '3D Platform - Nanotechnology (3)', 'Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9)', 'Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8)']","['Deduced Culture Strategy - 3D Only (157)', '3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74)', 'Contractile Analysis Method - Force Transducer (27)', 'Cell Coculture - Cardiomyocyte (157)', '3D Endothelial Cell Source - hiPSC-EndothelialC (16)', '3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74)', '3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119)', '3D Stromal Cell Source - hiPSC-MuralC (3)', '3D Platform - Fibrin (50)', 'Cell Line Ancestry - Caucasian (41)', '3D Estimated Cell Density (mil cells/mL) Quantiles - Q2 (>10 and ≤21) (17)', 'Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7)', '3D Tissue Media - MEM-α (60)', '3D Tissue Media - DMEM (53)', 'Differentiation Purity (%) Quantiles - Q1 (>95 and ≤99) (22)', 'Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10)', '3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31)', '3D Platform - Extracellular Scaffold (18)', 'Cell Line Sex - Female (40)', 'Maturation Strategy - Tension (64)', 'Publication Year - 2021 (43)', '3D Estimated Cell Density (mil cells/mL) Quantiles - Q3 (>5 and ≤10) (30)', 'Maturation Strategy - ECM (21)', 'Electrophysiology Analysis Method - Motion-Contrast Reconstruction (5)', 'Seeding Confluency 3D (%) - 70 to 79 (3)', '3D Tissue Media - Growth Factor (12)', 'Wnt Induction - Wnt3a (3)', 'Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10)', 'Cell Line - 201B6 (3)', 'Maturation Strategy - Electrical (39)', 'hiPSC Backbone Media - Conditioned (12)', 'Cell Line - C25 (6)', 'hiPSC-CM Purification Duration (days) - 6 days (10)', 'hiPSC Matrix Coating - Geltrex (33)', 'Journal - J Tissue Eng (4)', 'Wnt Induction Duration (days) - 3 days (38)', 'Journal - Circulation (11)', 'Pharmacological Intervention - Phenylephrine (3)', '3D Platform - 3D printed (9)']","['Metabolic Analysis Method - Genetic (3)', 'Sacromere or Cellular Alignment Analysis - Yes (72)', 'Electron Imaging - Transmission (62)', '2D Surface - ECM-coated (115)', 'Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11)', 'Differentiation Purity (%) Quantiles - Q4 (>79 and ≤85) (40)', 'Calcium Handling Analysis Method - Visual (104)', 'Journal - J Mol Cell Cardiol (4)', 'Coating for Replating - Matrigel (65)', 'Publication Year - 2022 (20)', 'Publication Year - 2018 (45)', '2D Surface - Electrospun (13)', 'Seeding Confluency (%) - 70 to 79 (11)', 'hiPSC-CM Backbone Media - RPMI-1640 (167)', 'hiPSC-CM Maturation Media - RPMI-1640 (153)', 'Journal - Rare (104)', 'Cell Line - Cor.4U (16)', 'Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12)', 'Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10)', 'Pharmacological Intervention - Verapamil (27)', 'Journal - Stem Cell Res (8)', 'Pharmacological Intervention - Phenylephrine (3)', 'Publication Year - 2024 (7)', 'Calcium Handling Analysis Method - Rare (4)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10)', 'Cell Line - WTC11 (30)', 'Seeding Confluency 2D (%) - 80 to 84 (5)', 'New Media for Maturation - F12 (7)', 'Electrophysiology Analysis Method - Motion-Contrast Reconstruction (5)', 'Purification Protocol - Metabolic (8)', 'Cell Line - Cellapy (4)', 'Metabolic Analysis Method - Flux Rates (13)', 'hiPSC-CM Maturation Media - Cor.4U Complete (6)', 'Pharmacological Intervention - Carbamylcholine (6)', 'Cell Line Sex - Male (64)']","['Publication Year - 2014 (3)', 'Cell Line - IMR90 (19)', 'Seeding Confluency (%) - 90 to 94 (26)', 'Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10)', 'Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6)', 'Sacromere or Cellular Alignment Analysis - Yes (72)', 'Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10)', 'Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8)', 'hiPSC Backbone Media - Conditioned (12)', 'Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12)', 'Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8)', 'Contractile Analysis Method - Traction Force Microscopy (9)', 'Electrophysiology Analysis Method - Patch Clamp (59)', 'Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10)', 'Journal - J Biomed Mater Res A (3)', 'Wnt Inhibitor - Wnt-C59 (30)', 'New Media for Maturation - F12 (7)', 'Metabolic Analysis Method - Genetic (3)', 'Number of Cell Lines - 4 (11)', 'Disease Modelling - Dilated Cardiomyopathy (6)', 'Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14)', 'Cell Line - Gibco episomal (10)', 'Seeding Confluency 2D (%) - 90 to 94 (12)', 'Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4)', 'Journal - J Mol Cell Card (6)', 'Pharmacological Intervention - Blebbistatin (5)', '2D Surface - Micropatterned (27)', 'Pharmacological Intervention - T3 (3)']","['Contractile Analysis Method - Traction Force Microscopy (9)', 'New Media for Maturation - RPMI-1640 (30)', '2D Surface - Micropatterned (27)', 'Journal - Stem Cell Res Ther (3)', 'Metabolic Analysis Method - Mitochondrial (4)', 'Maturation Strategy - Cell Alignment (59)', 'Cell Line Ancestry - Asian (28)', 'hiPSC Matrix Coating - Matrigel (163)', 'Journal - Stem Cell Reports (23)', 'Contractile Analysis Method - Deflection (39)', '3D Estimated Tissue Size (mm2) Quantiles - Q3 (>2 and ≤9.12) (21)', 'Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13)', 'Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8)', 'MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4)', 'Insulin Start Day - 6 (20)', 'Journal - Stem Cell Res (8)', 'Coating for Replating - Vitronectin (3)', 'Gene Analysis Method - Rare (5)', 'Day of Insulin Addition - not 22 (12)', 'Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10)', 'hiPSC-CM Media Supplement - B27 (180)', '3D CM Ratio (CM-EC-SC) Quantiles - Q2 (>75 and ≤91) (28)', 'Seeding Confluency 2D (%) - 90 to 94 (12)', 'Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13)', 'Disease Modelling - Specialised (3)', 'Pharmacological Intervention - Positive Inotropes (9)', 'hiPSC-CM Backbone Media - Rare (10)', 'Metabolic Component - Palmitic Acid (11)', 'hiPSC-CM Purification Duration (days) - 6 days (10)', 'Wnt Inhibitor - Wnt-C59 (30)', 'TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4)', 'Journal - PLoS One (9)']","['3D SC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤10) (29)', 'hiPSC Matrix Coating - Matrigel (163)', 'hiPSC Matrix Coating - Vitronectin (10)', 'Journal - PLoS One (9)', 'Journal - Biomaterials (16)', 'Purification Protocol - Glucose and Lactate (85)', 'hiPSC-CM Purification Duration (days) - 4 days (29)', 'Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13)', '3D Estimated Tissue Size (mm2) Quantiles - Q2 (>9.12 and ≤26.2) (26)', 'Contractile Analysis Method - Traction Force Microscopy (9)', 'Journal - Stem Cells Int (3)', 'Seeding Confluency 3D (%) - 85 to 89 (12)', 'Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10)', 'Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5)', 'Maturation Strategy - Tension (64)', 'Insulin Start Day - 1 (19)', 'hiPSC-CM Media Supplement - Ascorbic Acid (41)', '3D Tissue Media - High-glucose DMEM (9)', '3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74)', 'Journal - Stem Cells Transl Med (3)', 'Cell Line - Gibco episomal (10)', 'Wnt Inhibitor Duration (days) - 5 days (6)', 'Contractile Analysis Method - Force Transducer (27)', 'hiPSC Backbone Media - Essential 8 (82)', 'Publication Year - 2017 (43)', 'Cell Line - DF19-9-11T.H (16)', 'New Media for Maturation - RPMI-1640 (30)', 'Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10)', 'Electrophysiology Analysis Method - Genetic (3)', 'Day of Insulin Addition - not 17 (12)', 'Gene Analysis Method - RNA (169)', 'Maturation Strategy - Elastomeric (33)', '3D Platform - Gelatin (6)', 'Cell Line - WTC11 (30)', 'Journal - Stem Cells (11)', 'hiPSC-CM Media Supplement - B27 (180)', 'Insulin Start Day - 3 (5)', 'Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8)', 'Wnt Inhibitor - Wnt-C59 (30)', 'Differentiation Purity Assessment - IHC a-actinin (8)', 'Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11)']","['Contractile Analysis Method - Motion Tracking (93)', 'hiPSC Matrix Coating - Geltrex (33)', 'Journal - ACS Appl Mater Interfaces (4)', 'hiPSC Backbone Media - Essential 8 (82)', 'Purification Protocol - Glucose and Lactate (85)', 'Maturation Strategy - Mechanical (36)', 'Insulin Start Day - 7 (85)', 'hiPSC-CM Purification Duration (days) - 6 days (10)', 'Wnt Inhibitor - IWR (56)', 'Seeding Confluency (%) - 85 to 89 (43)', 'Insulin Start Day - 6 (20)', '2D Surface - Microparticle/fluid (3)', 'Fatty Acid Metabolism Assessed - Yes (20)', 'Calcium Handling Analysis Method - Rare (4)', 'Maturation Strategy - Cell Alignment (59)', 'Electron Imaging - Scanning (22)', '2D Surface - Electrospun (13)', 'Metabolic Component - Rare (4)', 'Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14)', 'Journal - Lab Chip (4)', 'Pharmacological Intervention - Other Antiarrhythmic Agents (13)', 'Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8)', 'Day of Insulin Addition - not 22 (12)', 'TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4)', 'Differentiation Purity Assessment - IHC cTnT (7)', 'MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4)', 'hiPSC-CM Purification Duration (days) - 3 days (13)', 'Pharmacological Intervention - Metoprolol (5)', 'Insulin Withdrawal Duration (days) Quantiles - Q1 (>4 and ≤10) (11)', 'hiPSC-CM Purification Duration (days) - 8 days (4)', 'Seeding Confluency 2D (%) - 85 to 89 (26)', 'Electrophysiology Analysis Method - Motion-Contrast Reconstruction (5)', 'Pharmacological Intervention - Carbamylcholine (6)', 'Cell Line Ancestry - Asian (28)', 'Insulin Withdrawal Duration (days) - 6 days (3)', 'hiPSC-CM Maturation Media - RPMI-1640 (153)', 'Journal - Biomater Sci (7)', 'Seeding Confluency 2D (%) - 80 to 84 (5)', 'Journal - Stem Cells (11)', 'Coating for Replating - Geltrex (10)']","['Journal - Stem Cell Reports (23)', 'Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10)', 'Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8)', 'Wnt Induction - StemCell Diff Kit (4)', 'Calcium Handling Analysis Method - Visual (104)', 'MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4)', 'Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10)', '3D CM Ratio (CM-EC-SC) Quantiles - Q2 (>75 and ≤91) (28)', 'Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9)', 'Cell Line - ATCC (5)', 'Maturation Strategy - Tension (64)', 'Differentiation Purity (%) Quantiles - Q4 (>79 and ≤85) (40)', 'Metabolic Analysis Method - Seahorse (35)', 'Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8)', 'Contractile Analysis Method - Deflection (39)', 'Differentiation Purity Assessment - Flow Cytometry cTnT+ (135)', 'Cell Line Ancestry - Asian (28)', 'TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4)', 'Publication Year - 2014 (3)', 'New Media for Maturation - Commercial Kit (5)', 'Cell Line - WTC11 (30)', 'Cell Line - IMR90 (19)', 'Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10)', 'Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14)', 'Wnt Inhibitor - XAV939 (24)', 'Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11)', 'hiPSC Backbone Media - Conditioned (12)', 'Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10)', 'Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9)', 'Maturation Strategy - ECM (21)', 'Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7)']","['2D Surface - Electrospun (13)', 'Publication Year - 2022 (20)', 'Calcium Handling Analysis Method - Visual (104)', 'Pharmacological Intervention - Phenylephrine (3)', 'Coating for Replating - Fibronectin (32)', '3D Estimated Tissue Size (mm2) Quantiles - Q3 (>2 and ≤9.12) (21)', 'Electron Imaging - Scanning (22)', 'hiPSC Backbone Media - StemFit (5)', 'Publication Year - Post 2020 (122)', 'Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14)', 'Seeding Confluency 3D (%) - 90 to 94 (13)', 'Contractile Analysis Method - Motion Tracking (93)', 'hiPSC-CM Maturation Media - iCell Maintenance (83)', 'Number of Cell Lines - 4 (11)', 'Journal - J Biomed Mater Res A (3)', 'hiPSC Matrix Coating - Geltrex (33)', 'Electrophysiology Analysis Method - Microelectrode (31)', 'Journal - Biomaterials (16)', 'Insulin Start Day - 9 (10)', 'Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9)', 'TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4)', '3D Stromal Cell Source - Dermal Fibroblast (7)', 'Cell Coculture - Endothelial Cell (35)', 'Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10)', 'Pharmacological Intervention - Thalidomide (3)', 'Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9)', 'Pharmacological Intervention - Cardiotoxic Agents (3)', 'Purification Protocol - Metabolic (8)', 'Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10)', 'Pharmacological Intervention - Blebbistatin (5)', 'Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4)', 'Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9)']","['Publication Year - 2021 (43)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10)', 'Coating for Replating - Rare (6)', 'Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11)', '3D Stromal Cell Source - Stromal Cell (35)', 'Seeding Confluency (%) - 80 to 84 (12)', 'Day of Insulin Addition - not 11 (5)', 'Pharmacological Intervention - T3 (3)', 'Metabolic Component Category - Metabolic Modulation (20)', 'Journal - Biomater Sci (7)', 'Metabolic Component - IGF-1 (3)', 'Cell Line Sex - Both (118)', 'Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10)', 'Sacromere or Cellular Alignment Analysis - Yes (72)', '3D Stromal Cell Source - hiPSC-SmoothMC (3)', 'Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14)', 'Wnt Inhibitor Duration (days) - 5 days (6)', 'Metabolic Component Category - Fatty Acids and Lipids (21)', 'Differentiation Purity Assessment - Visual Inspection (6)', 'Cell Line - DF19-9-11T.H (16)', '3D Stromal Cell Source - hiPSC-CardiacF (8)', 'Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5)', 'Differentiation Purity Assessment - Flow Cytometry cTnT+ (135)', 'Insulin Withdrawal Duration (days) - 4 days (18)', 'Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10)']","['Journal - Tissue Eng Part A (4)', 'Pharmacological Intervention - Adrenaline (83)', 'MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4)', 'Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13)', 'Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10)', 'Pharmacological Intervention - Verapamil (27)', 'Seeding Confluency 3D (%) - 80 to 84 (5)', 'Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13)', 'Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10)', 'Maturation Strategy - ECM (21)', 'Pharmacological Intervention - Isoproterenol (71)', 'Cell Line Ancestry - Asian (28)', 'Electron Imaging - Transmission (62)', 'Differentiation Purity (%) Quantiles - Q4 (>79 and ≤85) (40)', 'Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22)', 'hiPSC Backbone Media - mTeSR (106)', '3D Platform - Extracellular Scaffold (18)', 'Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11)', '3D Tissue Media - RPMI-1640 (72)', 'Journal - J Mol Cell Cardiol (4)', 'Pharmacological Intervention - Carbenoxolone (4)', '2D Surface - Decellularized ECM (3)', 'Cell Line - IMR90 (19)', 'Calcium Handling Analysis Method - Rare (4)', 'MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4)', '3D Tissue Media - Iscove (5)', 'Wnt Induction Duration (days) Quantiles - Q1 (>2 and ≤5) (61)', 'Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14)', 'Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10)', 'Journal - Biomater Sci (7)', 'Calcium Handling Analysis Method - Visual (104)']","['Journal - Am J Physiol Heart Circ Physiol (4)', 'Insulin Start Day - 5 (14)', 'Publication Year - 2018 (45)', 'hiPSC-CM Purification Duration (days) - 5 days (6)', 'Calcium Handling Analysis Method - Visual (104)', '3D Tissue Media - iCell Maintenance (12)', 'Journal - Tissue Eng Part A (4)', '2D Surface - Electrospun (13)', 'Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9)', 'Journal - J Biomed Mater Res A (3)', 'Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8)', 'hiPSC-CM Media Supplement - Rare (5)', 'Cell Line - iCell2 (8)', '3D CM Ratio (CM-EC-SC) Quantiles - Q2 (>75 and ≤91) (28)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10)', 'Differentiation Purity Assessment - IHC cTnT (7)', '3D Estimated Tissue Size (mm2) Quantiles - Q4 (>0.13 and ≤2) (31)', 'Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8)', 'Coating for Replating - Geltrex (10)', 'Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13)', 'Publication Year - 2022 (20)', '3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119)', 'Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7)', 'Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13)', 'Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11)', 'Wnt Induction - bFGF (45)', '3D Estimated Cell Density (mil cells/mL) Quantiles - Q2 (>10 and ≤21) (17)', '3D Tissue Media - Commercial Kit (21)', 'Disease Modelling - Genetic Disorders (18)', 'Journal - Sci Transl Med (3)']","['Electrophysiology Analysis Method - Optical Mapping (39)', 'Electron Imaging - Scanning (22)', 'Maturation Strategy - Mechanical (36)', 'Electron Imaging - Transmission (62)', '3D Tissue Media - High-glucose DMEM (9)', 'Wnt Inhibitor - IWR (56)', 'Journal - Cell Stem Cell (6)', 'Journal - ACS Appl Mater Interfaces (4)', 'Differentiation Purity Assessment - Flow Cytometry VCAM1+ (4)', '3D Tissue Media - iCell Maintenance (12)', '2D Surface - Micropatterned (27)', 'Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13)', 'Maturation Strategy - Electrical (39)', '3D Tissue Media - Commercial Kit (21)', '3D Estimated Tissue Size (mm2) Quantiles - Q4 (>0.13 and ≤2) (31)', '3D Platform - Scaffold Free (43)', 'Cell Line - Rare (132)', 'Metabolic Component Category - Signaling Pathway Regulators (6)', 'Journal - PLoS One (9)', '3D Tissue Media - Rare (13)', 'Electrophysiology Analysis Method - Microelectrode (31)', 'Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9)', 'Publication Year - 2016 (32)', 'TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4)', 'Publication Year - 2017 (43)', 'MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10)', 'Insulin Start Day - 4 (11)', 'Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5)']","['Electrophysiology Analysis Method - Patch Clamp (59)', 'Gene Analysis Method - RNA (169)', 'Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9)', 'Publication Year - 2017 (43)', 'Cell Line - ATCC (5)', 'Wnt Induction Duration (days) - 3 days (38)', 'Number of Cell Lines - 2 (50)', 'Wnt Inhibitor - XAV939 (24)', 'hiPSC Backbone Media - Rare (19)', 'Seeding Confluency (%) - 85 to 89 (43)', 'Coating for Replating - Gelatin (43)', 'Journal - Biomaterials (16)', 'Cell Line - BJ1 (7)', 'Wnt Inhibitor Duration (days) - >6 days (12)', 'Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10)', 'Number of Cell Lines - >5 (9)', 'Differentiation Purity (%) Quantiles - Q2 (>90 and ≤95) (27)', 'Seeding Confluency 2D (%) - 85 to 89 (26)', 'Metabolic Component - Fatty Acid (13)', 'Cell Line - iCell2 (8)', 'Metabolic Component Category - Sugars and Carbohydrates (9)', 'Journal - Sci Transl Med (3)', 'Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7)', 'Pharmacological Intervention - Other Antiarrhythmic Agents (13)', 'Journal - ACS Appl Mater Interfaces (4)', 'Wnt Inhibitor - IWP (112)', 'Cell Line - Rare (132)']","['Electrophysiology Analysis Method - Patch Clamp (59)', 'Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12)', 'Number of Cell Lines - 2 (50)', 'hiPSC Backbone Media - Conditioned (12)', 'Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10)', 'Journal - ACS Appl Mater Interfaces (4)', 'Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5)', 'Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13)', '3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47)', 'Wnt Induction - Activin A (80)', 'hiPSC Backbone Media - DMEM (10)', '3D Stromal Cell Source - hiPSC-MuralC (3)', 'Wnt Induction - BMP4 (74)', 'Publication Year - 2017 (43)', 'MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4)', 'Insulin Start Day - 4 (11)', 'Journal - Nano Lett (3)', 'Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14)', '3D Estimated Cell Density (mil cells/mL) Quantiles - Q2 (>10 and ≤21) (17)', 'Pharmacological Intervention - Carbenoxolone (4)', 'Wnt Induction - Wnt3a (3)', 'Wnt Inhibitor - KY02111 (7)', 'Differentiation Purity (%) Quantiles - Q2 (>90 and ≤95) (27)', 'Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6)', '3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24)', 'Maturation Strategy - Other Cells (80)', 'Wnt Inhibitor Duration (days) Quantiles - Q1 (>2 and ≤9) (58)', 'Differentiation Purity Assessment - IHC a-actinin (8)', 'Differentiation Purity Assessment - Flow Cytometry a-actinin+ (9)', 'Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7)']","['Electrophysiology Analysis Method - Motion-Contrast Reconstruction (5)', '3D Platform - Collagen (38)', 'Publication Year - 2018 (45)', 'Cell Line - Cor.4U (16)', 'hiPSC-CM Maturation Media - StemPro-34 (14)', 'hiPSC-CM Backbone Media - StemPro-34 (14)', 'Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10)', 'Differentiation Purity (%) Quantiles - Q5 (>30 and ≤79) (32)', 'hiPSC-CM Media Supplement - L-glutamine (19)', 'Seeding Confluency 3D (%) - 70 to 79 (3)', 'Journal - Biomater Sci (7)', '3D Stromal Cell Source - Human Fibroblast (38)', 'Maturation Strategy - Other Cells (80)', 'hiPSC-CM Media Supplement - Ascorbic Acid (41)', '3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119)', 'hiPSC Backbone Media - Conditioned (12)', 'Wnt Induction Duration (days) - 4 days (15)', 'Journal - Lab Chip (4)', 'Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11)', 'Differentiation Purity Assessment - Flow Cytometry cTnI+ (3)', 'Disease Modelling - Genetic Disorders (18)', 'Journal - Stem Cells Int (3)', 'Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8)', 'Journal - Tissue Eng Part A (4)', 'Journal - Stem Cell Res Ther (3)']","['TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4)', 'MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4)', 'MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4)', 'Journal - Nat Biomed Eng (5)', 'hiPSC-CM Media Supplement - Rare (5)', 'Journal - Tissue Eng Part A (4)', 'Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14)', 'Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10)', 'Insulin Start Day - 0 (7)', 'Calcium Handling Analysis Method - Rare (4)', 'TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4)', 'Number of Cell Lines - 3 (29)', 'Calcium Handling Analysis Method - Visual (104)', 'Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11)', 'Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13)', 'Gene Analysis Method - RNA (169)', 'Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12)', 'Pharmacological Intervention - T3 (3)', 'Seeding Confluency (%) - Rare (43)', 'Calcium Handling Analysis Method - Genetic (23)', 'Publication Year - 2014 (3)']","['TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4)', 'Contractile Analysis Method - Rare (7)', 'MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4)', 'MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4)', 'TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4)', 'Publication Year - 2019 (57)', 'Disease Modelling - Arrhythmic (15)', 'Disease Modelling - Ischemic Infarction (9)', '3D Stromal Cell Source - Stromal Cell (35)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10)', 'Journal - Tissue Eng Part A (4)', 'Metabolic Analysis Method - Seahorse (35)', 'Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9)', 'Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13)', 'Differentiation Purity (%) Quantiles - Q4 (>79 and ≤85) (40)', 'Disease Modelling - Genetic Disorders (18)', 'Journal - Nat Biomed Eng (5)', 'Calcium Handling Analysis Method - Visual (104)', 'Pharmacological Intervention - ACE Inhibitors (RAAS Modulators) (3)']","['MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4)', 'MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4)', 'MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4)', 'Contractile Analysis Method - Rare (7)', 'Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10)', 'Insulin Start Day - 0 (7)', 'Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11)', 'Disease Modelling - Arrhythmic (15)', 'Maturation Strategy - Mechanical (36)', 'Metabolic Component - Palmitic Acid (11)', 'Calcium Handling Analysis Method - Rare (4)', 'Metabolic Analysis Method - Seahorse (35)', 'MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11)', 'Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10)', 'Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13)', 'Maturation Strategy - Cell Alignment (59)', '2D Surface - Hydrogel (17)', 'Disease Modelling - Genetic Disorders (18)', 'Electron Imaging - Transmission (62)', 'Pharmacological Intervention - T3 (3)', 'Metabolic Component - IGF-1 (3)', 'Pharmacological Intervention - Phenylephrine (3)', 'Journal - Sci Adv (3)']","['3D Platform - Scaffold Free (43)', '3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28)', 'Deduced Culture Strategy - 3D Only (157)', '3D Tissue Media - Commercial Kit (21)', 'Cell Coculture - Cardiomyocyte (157)', '3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74)', 'Cell Coculture - Endothelial Cell (35)', '3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47)', '3D Estimated Tissue Size (mm2) Quantiles - Q4 (>0.13 and ≤2) (31)', '3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31)', '3D Tissue Media - Growth Factor (12)', 'Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108)', '3D Endothelial Cell Source - hiPSC-EndothelialC (16)', 'Electron Imaging - Transmission (62)', '3D Tissue Media - iCell Maintenance (12)', 'Differentiation Purity (%) Quantiles - Q1 (>95 and ≤99) (22)', '3D Stromal Cell Source - Cardiac Fibroblast (32)', '3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48)', '3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27)', 'Contractile Analysis Method - Motion Tracking (93)', 'hiPSC Backbone Media - StemFit (5)', 'Publication Year - 2021 (43)', 'Pharmacological Intervention - Traditional Chemotherapy Agents (18)', 'Differentiation Purity Assessment - Flow Cytometry VCAM1+ (4)', 'Day of Insulin Addition - not 17 (12)', '3D Tissue Media - MEM-α (60)', '3D Platform - 3D printed (9)', 'hiPSC-CM Backbone Media - Rare (10)', '3D Stromal Cell Source - Human Fibroblast (38)', 'Journal - Sci Rep (24)', 'Seeding Confluency 3D (%) - 85 to 89 (12)', 'Metabolic Analysis Method - Flux Rates (13)', '3D Stromal Cell Source - hiPSC-CardiacF (8)', 'Cell Line - iCell (47)', 'Pharmacological Intervention - Doxorubicin (17)', 'Purification Protocol - Antibiotic (4)']","['3D Platform - Scaffold Free (43)', 'Deduced Culture Strategy - 3D Only (157)', '3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24)', '3D Tissue Media - Commercial Kit (21)', 'Cell Coculture - Cardiomyocyte (157)', '3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119)', '3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47)', '3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74)', 'Electron Imaging - Transmission (62)', '3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74)', 'Contractile Analysis Method - Motion Tracking (93)', 'Journal - Nat Biomed Eng (5)', '3D Estimated Cell Density (mil cells/mL) Quantiles - Q4 (>0.47 and ≤5) (25)', 'hiPSC-CM Media Supplement - bFGF (3)', '3D Tissue Media - iCell Maintenance (12)', 'hiPSC-CM Maturation Media - Commercial Kit (27)', 'Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10)', 'Cell Line - WTC11 (30)', 'Maturation Strategy - Other Cells (80)', 'Journal - Rare (104)', 'Wnt Induction Duration (days) Quantiles - Q3 (>1 and ≤1) (186)', 'hiPSC-CM Media Supplement - VEGF (4)', '3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48)', 'Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8)', 'Metabolic Analysis Method - Flux Rates (13)', 'Coating for Replating - Fibronectin (32)', 'hiPSC-CM Backbone Media - Commercial CM Kit (12)', '3D Platform - 3D printed (9)']","['3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74)', '3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119)', 'Cell Coculture - Cardiomyocyte (157)', 'Deduced Culture Strategy - 3D Only (157)', '3D Tissue Media - RPMI-1640 (72)', '3D Platform - Scaffold Free (43)', 'Maturation Strategy - Tension (64)', '3D Platform - Fibrin (50)', '3D Estimated Cell Density (mil cells/mL) Quantiles - Q3 (>5 and ≤10) (30)', 'Seeding Confluency 3D (%) - Rare (26)', '3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28)', '3D Estimated Tissue Size (mm2) Quantiles - Q2 (>9.12 and ≤26.2) (26)', '3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27)', 'Seeding Confluency 3D (%) - 85 to 89 (12)', 'Wnt Inhibitor - DS-I-7 (9)']","['3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47)', '3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31)', 'Cell Coculture - Stromal Cell (78)', 'Maturation Strategy - Other Cells (80)', 'Cell Coculture - Endothelial Cell (35)', '3D Stromal Cell Source - Stromal Cell (35)', 'Cell Coculture - Cardiomyocyte (157)', '3D Stromal Cell Source - Human Fibroblast (38)', 'Deduced Culture Strategy - 3D Only (157)', '3D Platform - Collagen (38)', '3D Endothelial Cell Source - hiPSC-EndothelialC (16)', '3D Stromal Cell Source - Cardiac Fibroblast (32)', 'Maturation Strategy - Tension (64)', '3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119)', '3D Endothelial Cell Source - Umbilical Vein EndothelialC (10)', '3D Estimated Tissue Size (mm2) Quantiles - Q3 (>2 and ≤9.12) (21)', 'hiPSC Backbone Media - Conditioned (12)', '3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5)', '3D Estimated Cell Density (mil cells/mL) Quantiles - Q2 (>10 and ≤21) (17)', '3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28)', 'Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9)', '3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24)', '3D Stromal Cell Source - Mesenchymal Stem Cell (12)', '3D Endothelial Cell Source - Rare (3)', '3D Stromal Cell Source - Dermal Fibroblast (7)']","['3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74)', 'Cell Coculture - Cardiomyocyte (157)', 'Deduced Culture Strategy - 3D Only (157)', '3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74)', 'Maturation Strategy - Tension (64)', '3D Platform - Fibrin (50)', 'Contractile Analysis Method - Deflection (39)', 'Cell Coculture - Stromal Cell (78)', '3D CM Ratio (CM-EC-SC) Quantiles - Q2 (>75 and ≤91) (28)', '3D Estimated Cell Density (mil cells/mL) Quantiles - Q3 (>5 and ≤10) (30)', '3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48)', '3D SC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤10) (29)', '3D Estimated Tissue Size (mm2) Quantiles - Q2 (>9.12 and ≤26.2) (26)', '3D Tissue Media - RPMI-1640 (72)', '3D Estimated Tissue Size (mm2) Quantiles - Q4 (>0.13 and ≤2) (31)', '3D Platform - Scaffold Free (43)', 'Maturation Strategy - Other Cells (80)', '3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47)', '3D Platform - Collagen (38)', '3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24)', '3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28)', '3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27)', '3D Platform - Matrigel (33)', '3D Stromal Cell Source - Human Fibroblast (38)', '3D Stromal Cell Source - Stromal Cell (35)', 'Seeding Confluency 3D (%) - 85 to 89 (12)']","['Cell Coculture - Endothelial Cell (35)', '3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48)', '3D Endothelial Cell Source - hiPSC-EndothelialC (16)', 'Cell Coculture - Stromal Cell (78)', '3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47)', 'Maturation Strategy - Other Cells (80)', 'Deduced Culture Strategy - 3D Only (157)', '3D Endothelial Cell Source - Umbilical Vein EndothelialC (10)', 'Cell Coculture - Cardiomyocyte (157)', '3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5)', '3D Stromal Cell Source - Stromal Cell (35)', '3D Platform - 3D printed (9)', '3D Tissue Media - MEM-α (60)', '3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24)', 'Pharmacological Intervention - Doxorubicin (17)', '3D Stromal Cell Source - hiPSC-MuralC (3)', '3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24)', 'Maturation Strategy - Tension (64)', '3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27)', '3D Endothelial Cell Source - Rare (3)', 'Insulin Start Day - 9 (10)', '3D Stromal Cell Source - hiPSC-SmoothMC (3)', '3D Stromal Cell Source - hiPSC-CardiacF (8)', 'Journal - Front Cell Dev Biol (3)', 'Cell Line - 201B6 (3)']","['3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74)', '3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119)', 'Cell Coculture - Cardiomyocyte (157)', 'Deduced Culture Strategy - 3D Only (157)', '3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27)', '3D Tissue Media - RPMI-1640 (72)', 'Seeding Confluency 3D (%) - Rare (26)', '3D Platform - Fibrin (50)', '3D Estimated Cell Density (mil cells/mL) Quantiles - Q3 (>5 and ≤10) (30)', '3D Platform - Scaffold Free (43)', '3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28)', 'Wnt Inhibitor - DS-I-7 (9)', '3D Estimated Tissue Size (mm2) Quantiles - Q2 (>9.12 and ≤26.2) (26)', '3D Endothelial Cell Source - hiPSC-EndothelialC (16)', 'Seeding Confluency 3D (%) - 85 to 89 (12)', '3D Platform - 3D printed (9)', 'Wnt Inhibitor Duration (days) - >6 days (12)']","['3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48)', 'Cell Coculture - Stromal Cell (78)', '3D Stromal Cell Source - Stromal Cell (35)', 'Maturation Strategy - Other Cells (80)', 'Cell Coculture - Cardiomyocyte (157)', '3D Stromal Cell Source - Human Fibroblast (38)', 'Cell Coculture - Endothelial Cell (35)', 'Deduced Culture Strategy - 3D Only (157)', '3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31)', '3D Stromal Cell Source - Cardiac Fibroblast (32)', '3D Endothelial Cell Source - Umbilical Vein EndothelialC (10)', '3D Platform - Scaffold Free (43)', 'Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9)', '3D Platform - Collagen (38)', '3D CM Ratio (CM-EC-SC) Quantiles - Q2 (>75 and ≤91) (28)', '3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119)', '3D Stromal Cell Source - Mesenchymal Stem Cell (12)', '3D Estimated Tissue Size (mm2) Quantiles - Q3 (>2 and ≤9.12) (21)', 'Disease Modelling - Fibrotic (4)', '3D Endothelial Cell Source - hiPSC-EndothelialC (16)', '3D Stromal Cell Source - Dermal Fibroblast (7)']","['Publication Year - Post 2020 (122)', 'Publication Year - 2020 (51)', 'hiPSC-CM Purification Duration (days) Quantiles - Q2 (>1 and ≤4) (61)', 'T-tubule Structure (Found) Quantiles - Q1 (Yes) (18)', 'Sacromere or Cellular Alignment Analysis - Yes (72)', 'Maturation Strategy - Mechanical (36)', 'Disease Modelling - Hypertrophic Cardiomyopathy (6)', 'hiPSC-CM Purification Duration (days) - <3 days (31)', 'Contractile Analysis Method - Traction Force Microscopy (9)', 'Journal - Acta Biomater (10)', 'Electrophysiology Analysis Method - Patch Clamp (59)', 'Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9)', 'Journal - Biosens Bioelectron (4)', 'Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34)', 'Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9)', 'Coating for Replating - Fibronectin (32)', 'Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10)', 'Pharmacological Intervention - Carbenoxolone (4)', '3D Tissue Media - Growth Factor (12)', 'hiPSC Backbone Media - Conditioned (12)', 'Coating for Replating - Geltrex (10)', 'Journal - Nano Lett (3)', 'Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6)', 'New Media for Maturation - RPMI-1640 (30)', 'Cell Line - iCell2 (8)', 'Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11)', '2D Surface - Microparticle/fluid (3)', 'Coating for Replating - Rare (6)', 'Journal - Circ Res (5)', 'Differentiation Purity (%) Quantiles - Q2 (>90 and ≤95) (27)', 'Seeding Confluency 2D (%) - 95 to 100 (6)', 'Purification Protocol - Cell Sorting (7)']","['Sacromere or Cellular Alignment Analysis - Yes (72)', 'Insulin Start Day - 7 (85)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10)', 'Wnt Inhibitor Duration (days) - 5 days (6)', 'Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10)', 'hiPSC-CM Backbone Media - Commercial CM Kit (12)', '2D Surface - Micropatterned (27)', 'Metabolic Component - T3 (14)', 'Cell Line - Gibco episomal (10)', 'Disease Modelling - Dilated Cardiomyopathy (6)', 'Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10)', '3D Tissue Media - Iscove (5)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11)', 'hiPSC-CM Media Supplement - FBS (16)', 'Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10)', 'Deduced Culture Strategy - 2D Only (183)', 'hiPSC-CM Maturation Media - Commercial Kit (27)', 'Coating for Replating - Gelatin (43)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10)', 'TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4)', 'Day of Insulin Addition - not 21 (14)', 'Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9)', 'Seeding Confluency (%) - 85 to 89 (43)', 'Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13)', 'MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4)', 'MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4)', 'Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10)', 'Cell Line - BJ1 (7)', 'Publication Year - 2014 (3)', 'Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11)', '3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28)', 'Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8)', 'Wnt Inhibitor Duration (days) Quantiles - Q2 (>1 and ≤2) (156)']","['Wnt Inhibitor - XAV939 (24)', 'Sacromere or Cellular Alignment Analysis - Yes (72)', 'Cell Line - IMR90 (19)', 'Number of Cell Lines - 2 (50)', 'Electron Imaging - Transmission (62)', 'Insulin Start Day - 7 (85)', 'Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11)', 'Calcium Handling Analysis Method - Visual (104)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10)', '3D Tissue Media - RPMI-1640 (72)', 'Differentiation Purity (%) Quantiles - Q1 (>95 and ≤99) (22)', 'Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9)', 'hiPSC-CM Purification Duration (days) - 6 days (10)', 'Maturation Strategy - Electrical (39)', 'hiPSC Backbone Media - mTeSR (106)', '2D Surface - Micropatterned (27)', 'Journal - Nano Lett (3)', 'T-tubule Structure (Found) Quantiles - Q1 (Yes) (18)', 'Pharmacological Intervention - Adrenaline (83)', 'Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10)', 'Cell Line - DF19-9-11T.H (16)', 'Publication Year - 2016 (32)', 'Journal - Acta Biomater (10)', 'Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7)', 'Journal - ACS Appl Mater Interfaces (4)', 'Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5)', '2D Surface - Nanotopography (6)', 'Differentiation Purity Assessment - Visual Inspection (6)', 'New Media for Maturation - Rare (4)', '3D Platform - Polyethylene Glycol (8)', 'Contractile Analysis Method - Rare (7)', 'Pharmacological Intervention - Propranolol (5)', 'Differentiation Purity (%) Quantiles - Q5 (>30 and ≤79) (32)']","['Sacromere or Cellular Alignment Analysis - Yes (72)', 'Journal - Am J Physiol Heart Circ Physiol (4)', 'Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8)', 'Cell Line - IMR90 (19)', 'hiPSC Backbone Media - mTeSR (106)', 'Insulin Start Day - 7 (85)', 'Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10)', 'Seeding Confluency (%) - 70 to 79 (11)', 'Publication Year - 2016 (32)', 'Seeding Confluency 2D (%) - 80 to 84 (5)', 'Maturation Strategy - Metabolic (33)', 'Journal - Circ Res (5)', 'hiPSC Backbone Media - Embryonic Stem Cell (127)', 'TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4)', 'Pharmacological Intervention - Phenylephrine (3)', 'Electrophysiology Analysis Method - Patch Clamp (59)', 'Journal - J Mol Cell Cardiol (4)', 'Coating for Replating - Laminin (5)', 'Journal - Circulation (11)', 'Journal - Stem Cells Int (3)', 'Disease Modelling - Arrhythmic (15)', '3D Stromal Cell Source - Rare (4)', 'T-tubule Structure (Found) Quantiles - Q1 (Yes) (18)', 'Publication Year - 2017 (43)', 'Metabolic Component Category - Amino Acids and Derivatives (9)', 'Journal - Cell Stem Cell (6)', 'Metabolic Component - Rare (4)', 'Cell Line - DF19-9-11T.H (16)', 'Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14)', 'Pharmacological Intervention - Caffeine (4)', 'Seeding Confluency 2D (%) - 90 to 94 (12)', 'Seeding Confluency (%) - 80 to 84 (12)', 'Day of Insulin Addition - not 25 (3)', 'Metabolic Analysis Method - Mitochondrial (4)', 'Wnt Inhibitor - IWP (112)']","['Contractile Analysis Method - Force Transducer (27)', 'Journal - J Tissue Eng (4)', 'hiPSC-CM Media Supplement - FBS (16)', 'Cell Line Sex - Both (118)', 'hiPSC-CM Backbone Media - DMEM (18)', '3D Estimated Tissue Size (mm2) Quantiles - Q2 (>9.12 and ≤26.2) (26)', 'hiPSC-CM Maturation Media - DMEM (35)', 'Journal - J Tissue Eng Regen Med (3)', 'Publication Year - 2018 (45)', 'Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6)', '3D Platform - Fibrin (50)', '3D Stromal Cell Source - Rare (4)', 'Deduced Culture Strategy - 3D Only (157)', 'Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7)', 'Cell Line Sex - Female (40)', 'Cell Line - 201B7 (9)', 'hiPSC Matrix Coating - MEF feeder cells (8)', '3D Estimated Cell Density (mil cells/mL) Quantiles - Q3 (>5 and ≤10) (30)', 'Wnt Induction Duration (days) Quantiles - Q1 (>2 and ≤5) (61)', 'Cell Line - IMR90 (19)', 'hiPSC-CM Maturation Media - F12 (10)', 'Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13)', 'Journal - Stem Cells (11)', 'Maturation Strategy - Other Cells (80)', '3D Platform - Polyethylene Glycol (8)', 'hiPSC-CM Media Supplement - Mercaptoethanol (10)', 'Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34)', 'Differentiation Purity (%) Quantiles - Q2 (>90 and ≤95) (27)', 'Maturation Strategy - Mechanical (36)', 'Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13)', 'Wnt Induction Duration (days) - 4 days (15)', 'hiPSC-CM Media Supplement - Nonessential Amino Acids (8)', 'Calcium Handling Analysis Method - Visual (104)', 'Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9)', '3D Endothelial Cell Source - Rare (3)']","['Contractile Analysis Method - Deflection (39)', 'Publication Year - 2021 (43)', '3D Stromal Cell Source - Mesenchymal Stem Cell (12)', 'hiPSC-CM Media Supplement - Lipid Mix (5)', 'Wnt Inhibitor Duration (days) Quantiles - Q1 (>2 and ≤9) (58)', 'hiPSC-CM Backbone Media - StemPro-34 (14)', '3D CM Ratio (CM-EC-SC) Quantiles - Q2 (>75 and ≤91) (28)', 'Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34)', 'Disease Modelling - Genetic Disorders (18)', 'hiPSC-CM Maturation Media - StemPro-34 (14)', 'Seeding Confluency (%) - Rare (43)', '3D Stromal Cell Source - Stromal Cell (35)', '3D Tissue Media - MEM-α (60)', 'Cell Line - PGP1 (11)', 'hiPSC-CM Media Supplement - Selenium (7)', '3D Platform - Matrigel (33)', 'Cell Line - BJ RiPS (4)', 'Insulin Start Day - 6 (20)', 'Maturation Strategy - Tension (64)', 'hiPSC-CM Media Supplement - Polyvinylalchohol (6)', 'Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12)', '3D SC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤10) (29)', 'Maturation Strategy - ECM (21)', 'Publication Year - Post 2020 (122)', '3D Tissue Media - DMEM (53)', 'hiPSC-CM Media Supplement - Ascorbic Acid (41)', 'Maturation Strategy - Other Cells (80)', 'Publication Year - 2016 (32)', 'Journal - Lab Chip (4)', 'hiPSC-CM Media Supplement - Transferrin (11)', 'hiPSC-CM Media Supplement - Lipids (9)', 'Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8)', 'Wnt Inhibitor Duration (days) - 3 days (17)', 'Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10)', 'Insulin Start Day - 3 (5)', 'Journal - Stem Cell Res Ther (3)', 'Journal - ACS Biomater Sci Eng (3)', 'hiPSC-CM Maturation Media - Commercial Kit (27)', 'Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10)', 'Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5)', 'Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8)']","['Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11)', '3D Estimated Tissue Size (mm2) Quantiles - Q2 (>9.12 and ≤26.2) (26)', 'Maturation Strategy - Tension (64)', '3D Tissue Media - MEM-α (60)', 'Contractile Analysis Method - Deflection (39)', 'Insulin Withdrawal Duration (days) Quantiles - Q2 (>2 and ≤4) (25)', 'hiPSC-CM Media Supplement - HEPES (16)', '3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119)', '3D Estimated Tissue Size (mm2) Quantiles - Q3 (>2 and ≤9.12) (21)', '3D Platform - Fibrin (50)', '3D Tissue Media - DMEM (53)', '3D Estimated Cell Density (mil cells/mL) Quantiles - Q3 (>5 and ≤10) (30)', 'Journal - Stem Cell Reports (23)', 'Deduced Culture Strategy - 3D Only (157)', 'MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10)', 'Insulin Start Day - 6 (20)', 'Seeding Confluency 3D (%) - Rare (26)', 'Pharmacological Intervention - Rare (3)', '3D Platform - Extracellular Scaffold (18)', 'Gene Analysis Method - Rare (5)', 'Day of Insulin Addition - not 12 (11)', 'Journal - Circulation (11)', '3D Platform - Gelatin (6)', 'Insulin Withdrawal Duration (days) - 3 days (6)', 'Journal - Cell Stem Cell (6)', 'Number of Cell Lines - 4 (11)', 'TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4)']","['3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47)', '3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48)', 'Metabolic Component - Dexamethasone (7)', 'Maturation Strategy - Tension (64)', '3D Stromal Cell Source - Dermal Fibroblast (7)', '3D Tissue Media - RPMI-1640 (72)', '3D Stromal Cell Source - Cardiac Fibroblast (32)', 'Metabolic Component - IGF-1 (3)', '3D Platform - Fibrin (50)', 'Seeding Confluency 3D (%) - 90 to 94 (13)', 'Cell Coculture - Stromal Cell (78)', 'Deduced Culture Strategy - 3D Only (157)', 'Journal - Nat Biomed Eng (5)', '3D Estimated Cell Density (mil cells/mL) Quantiles - Q3 (>5 and ≤10) (30)', 'hiPSC Matrix Coating - MEF feeder cells (8)', '3D Stromal Cell Source - Human Fibroblast (38)', '3D Platform - Extracellular Scaffold (18)', '3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119)', 'Contractile Analysis Method - Deflection (39)', 'Publication Year - Post 2020 (122)', 'Maturation Strategy - Other Cells (80)', 'Insulin Start Day - 11 (3)', '3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24)', 'Number of Cell Lines - 4 (11)', 'Journal - PLoS One (9)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11)', 'Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7)', 'Journal - ACS Biomater Sci Eng (3)', 'Journal - J Mol Cell Card (6)', 'Maturation Strategy - Metabolic (33)', 'Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18)', 'Journal - J Mol Cell Cardiol (4)']","['3D Estimated Cell Density (mil cells/mL) Quantiles - Q2 (>10 and ≤21) (17)', 'Cell Line - 201B6 (3)', '3D Platform - Collagen (38)', 'hiPSC-CM Purification Duration (days) - 4 days (29)', 'Contractile Analysis Method - Force Transducer (27)', 'Wnt Induction - Wnt3a (3)', '3D Platform - Matrigel (33)', 'Journal - Biosens Bioelectron (4)', '3D Stromal Cell Source - hiPSC-MuralC (3)', '3D Stromal Cell Source - Stromal Cell (35)', 'Maturation Strategy - Tension (64)', 'Cell Line - iCell2 (8)', '3D Endothelial Cell Source - hiPSC-EndothelialC (16)', 'Coating for Replating - Laminin (5)', 'Wnt Induction - Activin A (80)', 'Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7)', 'Cell Line Sex - Female (40)', 'Contractile Analysis Method - Traction Force Microscopy (9)', 'Wnt Inhibitor - XAV939 (24)', 'Publication Year - 2021 (43)', 'Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8)', '3D Stromal Cell Source - Mesenchymal Stem Cell (12)', '3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27)', 'Cell Coculture - Stromal Cell (78)', 'Day of Insulin Addition - not 10 (4)', '3D Estimated Tissue Size (mm2) Quantiles - Q2 (>9.12 and ≤26.2) (26)', 'hiPSC Backbone Media - Conditioned (12)', 'Maturation Strategy - Mechanical (36)', 'Electrophysiology Analysis Method - Motion-Contrast Reconstruction (5)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11)', 'Journal - Sci Transl Med (3)', 'Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4)', 'Wnt Induction Duration (days) - 5 days (8)']","['Contractile Analysis Method - Motion Tracking (93)', '3D Tissue Media - RPMI-1640 (72)', 'Publication Year - 2021 (43)', 'Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10)', '3D Platform - Gelatin (6)', 'Pharmacological Intervention - Cardiotoxic Agents (3)', 'Day of Insulin Addition - not 23 (10)', 'Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6)', '3D Platform - Fibronectin (3)', 'Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8)', 'Journal - Biomaterials (16)', 'Day of Insulin Addition - not 21 (14)', 'Journal - J Mol Cell Cardiol (4)', '3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28)', 'Day of Insulin Addition - not 24 (9)', 'Metabolic Component Category - Kinase Inhibitors (3)', 'Wnt Induction Duration (days) Quantiles - Q2 (>1 and ≤2) (75)', 'Journal - Nat Commun (13)', 'Journal - ACS Biomater Sci Eng (3)', 'Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10)', '3D Platform - 3D printed (9)', 'Seeding Confluency 2D (%) - 90 to 94 (12)', 'Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11)', 'Pharmacological Intervention - Thalidomide (3)', 'Cell Line - Cellapy (4)', 'Seeding Confluency 3D (%) - 70 to 79 (3)', '3D Platform - Polyethylene Glycol (8)', 'Insulin Withdrawal Duration (days) Quantiles - Q2 (>2 and ≤4) (25)', 'Differentiation Purity Assessment - IHC cTnT (7)', 'Insulin Start Day - 9 (10)', 'hiPSC-CM Maturation Media - Commercial Kit (27)', 'Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10)']","['Journal - Biomater Sci (7)', 'Sacromere or Cellular Alignment Analysis - Yes (72)', 'Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13)', '2D Surface - Decellularized ECM (3)', 'Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10)', 'Cell Line - 253G1 (10)', 'Contractile Analysis Method - Motion Tracking (93)', '3D Platform - Polyethylene Glycol (8)', 'Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4)', '3D Tissue Media - DMEM (53)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10)', 'Calcium Handling Analysis Method - Visual (104)', 'Contractile Analysis Method - Rare (7)', 'Wnt Inhibitor - Rare (3)', 'Wnt Inhibitor - IWP (112)', '3D Stromal Cell Source - hiPSC-SmoothMC (3)', '2D Surface - Micropatterned (27)', 'Insulin Start Day - 7 (85)', 'Seeding Confluency 2D (%) - 85 to 89 (26)', 'Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10)', 'Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8)', 'Number of Cell Lines - 4 (11)', 'Journal - Acta Biomater (10)', 'Seeding Confluency 2D (%) - Rare (13)', 'Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9)', 'Publication Year - 2017 (43)', 'Seeding Confluency (%) - 85 to 89 (43)']","['Electron Imaging - Transmission (62)', 'Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14)', 'Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10)', 'Electrophysiology Analysis Method - Patch Clamp (59)', '3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28)', 'Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10)', 'Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10)', 'Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14)', 'Electron Imaging - Scanning (22)', 'Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5)', 'Maturation Strategy - Cell Alignment (59)', 'Metabolic Analysis Method - Genetic (3)', 'Metabolic Analysis Method - Flux Rates (13)', 'Journal - ACS Appl Mater Interfaces (4)', 'Cell Line Ancestry - Asian (28)', 'Journal - Acta Biomater (10)', '3D Tissue Media - Commercial Kit (21)', 'Publication Year - 2024 (7)', 'Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7)', '3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5)', 'Wnt Induction Duration (days) Quantiles - Q3 (>1 and ≤1) (186)', 'Journal - PLoS One (9)', 'Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8)', 'Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8)', '3D Stromal Cell Source - Rare (4)', 'Sacromere or Cellular Alignment Analysis - Yes (72)', 'Differentiation Purity Assessment - Flow Cytometry VCAM1+ (4)', 'Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12)', 'Maturation Strategy - Electrical (39)', 'Seeding Confluency (%) - 85 to 89 (43)', 'Cell Line - iCell (47)', 'New Media for Maturation - DMEM (21)']","['Seeding Confluency 2D (%) - 80 to 84 (5)', 'Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7)', 'Calcium Handling Analysis Method - Genetic (23)', 'Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10)', 'Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13)', 'Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10)', 'Journal - Nano Lett (3)', 'Calcium Handling Analysis Method - Visual (104)', 'Maturation Strategy - Other Cells (80)', 'Seeding Confluency (%) - 80 to 84 (12)', 'Insulin Start Day - 7 (85)', '3D Stromal Cell Source - Stromal Cell (35)', 'Sacromere or Cellular Alignment Analysis - Yes (72)', 'MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4)', '3D Platform - Scaffold Free (43)', 'Publication Year - 2015 (19)', 'Journal - J Mol Cell Cardiol (4)', 'Journal - Tissue Eng Part A (4)', 'Cell Line - DF19-9-11T.H (16)', 'Cell Line - 253G1 (10)', 'Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11)', 'Journal - J Mol Cell Card (6)', '3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24)', 'Coating for Replating - Rare (6)', 'Cell Line - Gibco episomal (10)', '3D Tissue Media - iCell Maintenance (12)', '2D Surface - Nanotopography (6)', 'Publication Year - 2018 (45)', 'MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4)', 'Disease Modelling - Fibrotic (4)', '3D Tissue Media - High-glucose DMEM (9)']","['Metabolic Component - Dexamethasone (7)', 'Calcium Handling Analysis Method - Visual (104)', 'Metabolic Component - T3 (14)', 'Seeding Confluency (%) - 80 to 84 (12)', 'Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13)', 'Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6)', 'Seeding Confluency 3D (%) - 80 to 84 (5)', 'Metabolic Component - IGF-1 (3)', 'Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10)', '3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47)', 'Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14)', 'Maturation Strategy - ECM (21)', '3D Platform - Extracellular Scaffold (18)', 'Journal - J Mol Cell Card (6)', 'Pharmacological Intervention - Adrenaline (83)', 'Journal - Tissue Eng Part A (4)', 'Publication Year - 2018 (45)', 'Seeding Confluency 2D (%) - 90 to 94 (12)', 'Journal - Nat Biomed Eng (5)', 'Cell Line - IMR90 (19)', 'Metabolic Component Category - Hormonal Stimulation (14)', 'Seeding Confluency 2D (%) - 95 to 100 (6)', 'Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12)', 'Wnt Inhibitor - IWR (56)', 'Wnt Inhibitor Duration (days) Quantiles - Q1 (>2 and ≤9) (58)', 'Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7)']","['Journal - Biomater Sci (7)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10)', 'Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7)', 'Journal - Circ Res (5)', 'Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5)', 'Sacromere or Cellular Alignment Analysis - Yes (72)', 'hiPSC-CM Backbone Media - Commercial CM Kit (12)', '3D Tissue Media - Iscove (5)', 'Calcium Handling Analysis Method - Visual (104)', 'Pharmacological Intervention - Carbamylcholine (6)', 'Contractile Analysis Method - Motion Tracking (93)', 'Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5)', '3D Endothelial Cell Source - Umbilical Vein EndothelialC (10)', 'Cell Line - PGP1 (11)', 'Differentiation Purity (%) Quantiles - Q4 (>79 and ≤85) (40)', 'Seeding Confluency (%) - 85 to 89 (43)', 'Wnt Induction - StemCell Diff Kit (4)', 'hiPSC Backbone Media - Embryonic Stem Cell (127)', 'Disease Modelling - Hypertrophic Cardiomyopathy (6)', '3D Tissue Media - High-glucose DMEM (9)', 'Journal - Nat Biomed Eng (5)', 'Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9)', 'Disease Modelling - Rare (4)', 'Pharmacological Intervention - Lidocaine (7)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11)', 'New Media for Maturation - Commercial Kit (5)', 'Maturation Strategy - Cell Alignment (59)', 'Differentiation Purity Assessment - IHC cTnT (7)', 'Seeding Confluency 2D (%) - 95 to 100 (6)', 'Pharmacological Intervention - Propranolol (5)', 'Differentiation Purity Assessment - Flow Cytometry a-actinin+ (9)', 'Publication Year - 2018 (45)', 'Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8)', 'Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11)', 'Cell Line - Rare (132)']","['2D Surface - Micropatterned (27)', 'hiPSC Backbone Media - StemFlex (5)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10)', 'Calcium Handling Analysis Method - Visual (104)', 'Journal - Tissue Eng Part A (4)', '3D Stromal Cell Source - Stromal Cell (35)', 'Seeding Confluency 2D (%) - 70 to 79 (6)', 'Pharmacological Intervention - Isoproterenol (71)', 'Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73)', 'Electrophysiology Analysis Method - Optical Mapping (39)', 'Calcium Handling Analysis Method - Genetic (23)', 'Maturation Strategy - Elastomeric (33)', 'Publication Year - 2016 (32)', 'Pharmacological Intervention - Adrenaline (83)', 'Metabolic Component Category - Kinase Inhibitors (3)', 'Insulin Start Day - 7 (85)', 'Journal - Am J Physiol Heart Circ Physiol (4)', 'Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11)', 'Number of Cell Lines - 3 (29)', 'Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10)', 'Cell Line - WTC11 (30)', '3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24)', 'Insulin Withdrawal Duration (days) - 8 days (3)', 'Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10)', 'Cell Line Ancestry - Asian (28)', '3D Estimated Tissue Size (mm2) Quantiles - Q2 (>9.12 and ≤26.2) (26)', 'Metabolic Component Category - Signaling Pathway Regulators (6)', '3D Platform - Polyethylene Glycol (8)', '3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119)', 'Seeding Confluency 3D (%) - 80 to 84 (5)', 'Differentiation Purity (%) Quantiles - Q2 (>90 and ≤95) (27)', 'hiPSC-CM Purification Duration (days) - 5 days (6)', 'Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10)']","['Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10)', '3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11)', 'hiPSC Matrix Coating - Vitronectin (10)', 'Cell Line Sex - Both (118)', 'Publication Year - 2018 (45)', '3D Platform - Scaffold Free (43)', 'Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10)', 'Seeding Confluency (%) - 80 to 84 (12)', 'Wnt Inhibitor - IWR (56)', 'Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14)', 'Coating for Replating - Vitronectin (3)', 'Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14)', '3D Estimated Cell Density (mil cells/mL) Quantiles - Q2 (>10 and ≤21) (17)', '3D Stromal Cell Source - Rare (4)', 'Seeding Confluency 3D (%) - 80 to 84 (5)', 'Journal - Stem Cell Reports (23)', 'Cell Line - IMR90 (19)', 'Differentiation Purity Assessment - Flow Cytometry VCAM1+ (4)', 'Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34)', 'Calcium Handling Analysis Method - Visual (104)', 'Calcium Handling Analysis Method - Rare (4)', 'Number of Cell Lines - 4 (11)', '2D Surface - Microelectrode Array (9)', 'Cell Line - Gibco episomal (10)']","['Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9)', '3D Stromal Cell Source - Mesenchymal Stem Cell (12)', 'Pharmacological Intervention - Cisapride (8)', '3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24)', 'Contractile Analysis Method - Deflection (39)', 'Calcium Handling Analysis Method - Visual (104)', '3D Stromal Cell Source - Stromal Cell (35)', 'Cell Coculture - Stromal Cell (78)', 'Seeding Confluency 2D (%) - 70 to 79 (6)', 'Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11)', 'Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8)', 'Seeding Confluency 3D (%) - 90 to 94 (13)', 'Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5)', 'Pharmacological Intervention - QT-Prolonging Drugs (36)', 'Journal - Biomaterials (16)', 'Journal - Circulation (11)', '3D Estimated Cell Density (mil cells/mL) Quantiles - Q3 (>5 and ≤10) (30)', '3D Platform - Nanotechnology (3)', 'Wnt Induction Duration (days) - 3 days (38)', '3D Estimated Tissue Size (mm2) Quantiles - Q3 (>2 and ≤9.12) (21)', 'Pharmacological Intervention - Carbenoxolone (4)', 'Insulin Start Day - After 11 (7)', 'Metabolic Component Category - Kinase Inhibitors (3)', 'hiPSC Backbone Media - StemFlex (5)', '3D Tissue Media - High-glucose DMEM (9)', 'Seeding Confluency (%) - 70 to 79 (11)', 'Insulin Start Day - 2 (4)', '3D Endothelial Cell Source - Umbilical Vein EndothelialC (10)']","['Seeding Confluency 2D (%) - 90 to 94 (12)', 'Sacromere or Cellular Alignment Analysis - Yes (72)', 'Calcium Handling Analysis Method - Visual (104)', 'Differentiation Purity (%) Quantiles - Q1 (>95 and ≤99) (22)', 'Journal - Rare (104)', 'Maturation Strategy - Other Cells (80)', 'Cell Line Sex - Both (118)', 'Day of Insulin Addition - not 15 (16)', '2D Surface - Decellularized ECM (3)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10)', 'Publication Year - 2024 (7)', 'Insulin Start Day - 8 (15)', 'hiPSC-CM Purification Duration (days) - 4 days (29)', 'Maturation Strategy - Electrical (39)', 'Calcium Handling Analysis Method - Rare (4)', 'Pharmacological Intervention - Adrenaline (83)', 'Differentiation Purity Assessment - Rare (3)', 'Day of Insulin Addition - not 16 (15)', 'Day of Insulin Addition - not 14 (15)', 'Seeding Confluency 2D (%) - 70 to 79 (6)', 'Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14)', 'Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10)', 'Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12)', 'MYL2 Precentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10)', 'Seeding Confluency (%) - 90 to 94 (26)', 'Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9)', 'hiPSC Matrix Coating - Vitronectin (10)', 'Publication Year - 2019 (57)', '3D Platform - Matrigel (33)', 'TNNI3 Precentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4)']","['Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10)', 'Gene Analysis Method - Rare (5)', 'Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34)', 'Disease Modelling - Dilated Cardiomyopathy (6)', 'Insulin Start Day - 0 (7)', 'Calcium Handling Analysis Method - Visual (104)', 'Journal - Cell Stem Cell (6)', 'Journal - Am J Physiol Heart Circ Physiol (4)', 'Insulin Start Day - 1 (19)', 'hiPSC-CM Purification Duration (days) Quantiles - Q2 (>1 and ≤4) (61)', 'hiPSC-CM Media Supplement - Polyvinylalchohol (6)', 'Pharmacological Intervention - Isoproterenol (71)', 'Insulin Start Day - 10 (6)', 'Differentiation Purity Assessment - IHC a-actinin (8)', 'Journal - Stem Cells (11)', 'New Media for Maturation - Commercial Kit (5)', 'Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9)', 'Pharmacological Intervention - Cisapride (8)', 'Journal - Stem Cell Res (8)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11)', 'Journal - Nano Lett (3)', 'Publication Year - 2015 (19)', 'Publication Year - 2020 (51)', 'Insulin Start Day - 11 (3)', 'hiPSC-CM Media Supplement - Lipids (9)', 'Pharmacological Intervention - Carbenoxolone (4)', 'Journal - ACS Biomater Sci Eng (3)', 'Journal - Biomater Sci (7)', '3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24)', 'Electrophysiology Analysis Method - Genetic (3)', 'Differentiation Purity Assessment - Flow Cytometry cTnI+ (3)', 'Seeding Confluency 3D (%) - 85 to 89 (12)', 'Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11)', 'Metabolic Analysis Method - Seahorse (35)', 'Disease Modelling - Rare (4)']","['Cell Line - Rare (132)', 'Seeding Confluency 3D (%) - 70 to 79 (3)', 'Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7)', '2D Surface - Decellularized ECM (3)', 'hiPSC-CM Media Supplement - Nonessential Amino Acids (8)', '3D Platform - Gelatin (6)', 'Journal - Tissue Eng Part C Methods (6)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10)', 'Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10)', 'Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9)', 'Pharmacological Intervention - Class Ic Antiarrhythmics (Na+ Channel Blockers - Strong Blockade) (9)', 'Journal - ACS Appl Mater Interfaces (4)', '3D Stromal Cell Source - Rare (4)', 'Insulin Start Day - 8 (15)', 'Cell Line Ancestry - Caucasian (41)', 'hiPSC-CM Media Supplement - Mercaptoethanol (10)', '3D CM Ratio (CM-EC-SC) Quantiles - Q2 (>75 and ≤91) (28)', 'Seeding Confluency (%) - 85 to 89 (43)', 'Wnt Inhibitor - IWR (56)', 'Calcium Handling Analysis Method - Visual (104)', 'Insulin Withdrawal Duration (days) - 8 days (3)', 'Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14)', 'Journal - Stem Cell Res Ther (3)', 'Gene Analysis Method - Rare (5)', 'Journal - Biomaterials (16)', 'Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13)', 'Electron Imaging - Scanning (22)', '3D Endothelial Cell Source - hiPSC-EndothelialC (16)', 'Wnt Inhibitor - IWP (112)', 'Coating for Replating - Vitronectin (3)', '3D Stromal Cell Source - hiPSC-SmoothMC (3)']","['Purification Protocol - Cell Sorting (7)', '2D Surface - Microelectrode Array (9)', 'Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11)', 'Publication Year - 2016 (32)', 'hiPSC-CM Media Supplement - Albumin (28)', 'Metabolic Analysis Method - Genetic (3)', 'Pharmacological Intervention - Caffeine (4)', 'Publication Year - 2018 (45)', 'Insulin Start Day - After 11 (7)', 'Insulin Start Day - 2 (4)', 'Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13)', 'Pharmacological Intervention - QT-Prolonging Drugs (36)', 'Metabolic Component - Dexamethasone (7)', 'hiPSC-CM Media Supplement - GlutaMax (8)', 'Disease Modelling - Specialised (3)', '3D Stromal Cell Source - hiPSC-SmoothMC (3)', 'Maturation Strategy - Mechanical (36)', 'Electrophysiology Analysis Method - Microelectrode (31)', '3D Tissue Media - Rare (13)', 'Journal - Stem Cells Int (3)', 'Metabolic Component - Palmitic Acid (11)', '2D Surface - Micropatterned (27)', 'Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8)', 'Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10)', 'hiPSC-CM Backbone Media - Cor.4U Complete (6)', 'Journal - Biomaterials (16)', 'Differentiation Purity Assessment - Flow Cytometry SIRPA+ (4)', 'Publication Year - 2014 (3)', 'hiPSC-CM Media Supplement - bFGF (3)', 'Journal - Stem Cells (11)', 'Journal - Circulation (11)']","['Disease Modelling - Arrhythmic (15)', 'Insulin Start Day - 9 (10)', 'Differentiation Purity Assessment - IHC a-actinin (8)', 'Electrophysiology Analysis Method - Optical Mapping (39)', 'Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14)', 'Coating for Replating - Gelatin (43)', 'Publication Year - 2020 (51)', 'Journal - Biosens Bioelectron (4)', 'Day of Insulin Addition - not 9 (3)', 'Wnt Inhibitor - Rare (3)', 'T-tubule Structure (Found) Quantiles - Q1 (Yes) (18)', 'Pharmacological Intervention - Cisapride (8)', 'Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5)', 'Cell Line - iCell2 (8)', 'Calcium Handling Analysis Method - Visual (104)', 'Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34)', 'Pharmacological Intervention - Carbenoxolone (4)', 'Cell Line - ATCC (5)', 'Coating for Replating - Laminin (5)', 'Journal - J Mol Cell Cardiol (4)', 'Seeding Confluency 3D (%) - 80 to 84 (5)', 'Maturation Strategy - ECM (21)', 'Day of Insulin Addition - not 10 (4)', '3D Stromal Cell Source - hiPSC-SmoothMC (3)', 'Pharmacological Intervention - E4031 (22)', 'Journal - Nano Lett (3)', 'Metabolic Component - IGF-1 (3)', 'Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10)', 'Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9)', 'Sacromere or Cellular Alignment Analysis - Yes (72)']","['Electrophysiology Analysis Method - Patch Clamp (59)', 'Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12)', 'Cell Line - C25 (6)', 'Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10)', 'Pharmacological Intervention - E4031 (22)', 'Journal - Stem Cells (11)', 'Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9)', 'Journal - Cell Stem Cell (6)', 'Pharmacological Intervention - QT-Prolonging Drugs (36)', 'hiPSC Backbone Media - Rare (19)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10)', 'Metabolic Analysis Method - Seahorse (35)', '3D Stromal Cell Source - Rare (4)', 'Wnt Inhibitor - KY02111 (7)', 'Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9)', 'hiPSC-CM Media Supplement - Polyvinylalchohol (6)', 'Insulin Start Day - 6 (20)', 'Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8)', 'Number of Cell Lines - 3 (29)', 'Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22)', 'hiPSC-CM Media Supplement - Selenium (7)', 'Calcium Handling Analysis Method - Rare (4)', 'hiPSC-CM Media Supplement - Lipids (9)']","['Electrophysiology Analysis Method - Patch Clamp (59)', 'Insulin Start Day - 2 (4)', 'Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8)', 'Journal - Int J Mol Sci (3)', 'Number of Cell Lines - 4 (11)', 'hiPSC Matrix Coating - Matrigel (163)', 'Purification Protocol - Cell Sorting (7)', 'Pharmacological Intervention - Caffeine (4)', '2D Surface - Electrospun (13)', 'New Media for Maturation - Commercial Kit (5)', 'Wnt Induction - Rare (4)', 'hiPSC-CM Media Supplement - Lipids (9)', 'Pharmacological Intervention - E4031 (22)', 'Wnt Induction - BMP4 (74)', 'Insulin Start Day - 8 (15)', '2D Surface - Microelectrode Array (9)', 'Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12)', 'Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10)', 'Wnt Inhibitor Duration (days) - 4 days (19)', 'hiPSC-CM Purification Duration (days) - <3 days (31)', 'Seeding Confluency (%) - 70 to 79 (11)', 'Electrophysiology Analysis Method - Microelectrode (31)', 'Differentiation Purity Assessment - Flow Cytometry VCAM1+ (4)', 'Wnt Inhibitor - bFGF (8)', 'Coating for Replating - Matrigel (65)', 'Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8)', 'Purification Protocol - Metabolic (8)', 'Cell Line - iCell (47)', 'Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8)', 'hiPSC-CM Media Supplement - Albumin (28)', 'New Media for Maturation - F12 (7)', 'Cell Line - BJ1 (7)']","['Electrophysiology Analysis Method - Patch Clamp (59)', 'Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10)', 'hiPSC-CM Maturation Media - RPMI-1640 (153)', 'Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9)', 'hiPSC-CM Backbone Media - RPMI-1640 (167)', 'Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8)', 'Pharmacological Intervention - Other Antiarrhythmic Agents (13)', 'Publication Year - 2015 (19)', 'Coating for Replating - Synthemax (3)', 'Journal - Tissue Eng Part C Methods (6)', 'Seeding Confluency (%) - Rare (43)', 'Pharmacological Intervention - E4031 (22)', 'Calcium Handling Analysis Method - Genetic (23)', 'Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12)', '3D Stromal Cell Source - Cardiac Fibroblast (32)', 'Cell Line Ancestry - Asian (28)', '3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5)', 'Pharmacological Intervention - Lidocaine (7)', 'Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12)', 'Journal - Sci Transl Med (3)', 'Cell Line Sex - Both (118)', 'Wnt Induction - bFGF (45)', 'Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14)', 'Cell Line - iCell2 (8)', 'Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4)']","['Electrophysiology Analysis Method - Patch Clamp (59)', 'Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10)', 'Journal - Int J Mol Sci (3)', 'Seeding Confluency (%) - 70 to 79 (11)', 'Journal - Am J Physiol Heart Circ Physiol (4)', 'Cell Line - C25 (6)', 'Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10)', 'Coating for Replating - Laminin (5)', 'Journal - PLoS One (9)', 'Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10)', 'hiPSC Matrix Coating - EBs (18)', 'hiPSC-CM Purification Duration (days) - 6 days (10)', 'Disease Modelling - Genetic Disorders (18)', 'Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13)', 'hiPSC Backbone Media - Rare (19)', 'Cell Line - BJ RiPS (4)', 'Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10)', 'Pharmacological Intervention - Carbamylcholine (6)', 'Publication Year - Late-2010s (196)', 'Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10)', 'Seeding Confluency 2D (%) - 70 to 79 (6)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10)', '2D Surface - Electrospun (13)', 'Insulin Start Day - 3 (5)', 'Cell Line Sex - Female (40)', 'Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14)', 'Wnt Inhibitor Duration (days) - 5 days (6)', 'Publication Year - 2017 (43)']","['Electrophysiology Analysis Method - Patch Clamp (59)', 'Journal - Cell Stem Cell (6)', 'Number of Cell Lines - 4 (11)', 'Electron Imaging - Transmission (62)', 'Metabolic Component - Palmitic Acid (11)', '3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28)', '3D Stromal Cell Source - Rare (4)', 'Disease Modelling - Genetic Disorders (18)', 'Metabolic Component - Dexamethasone (7)', 'Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8)', 'Journal - Nat Commun (13)', 'Wnt Induction - BMP4 (74)', 'Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10)', 'Metabolic Component - Galactose (4)', 'Calcium Handling Analysis Method - Visual (104)', 'Seeding Confluency 3D (%) - 95 to 100 (13)', 'Metabolic Analysis Method - Seahorse (35)', 'hiPSC-CM Media Supplement - Ascorbic Acid (41)', '3D Platform - Scaffold Free (43)', 'hiPSC-CM Media Supplement - 1-thioglycerol (14)', 'Differentiation Purity Assessment - Flow Cytometry SIRPA+ (4)', '3D Tissue Media - Growth Factor (12)', 'Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13)', 'Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10)', 'Wnt Inhibitor - VEGF (3)', 'hiPSC-CM Backbone Media - StemPro-34 (14)', 'Insulin Start Day - 2 (4)', 'Wnt Inhibitor - bFGF (8)', 'Pharmacological Intervention - Caffeine (4)', 'Purification Protocol - Cell Sorting (7)', 'T-tubule Structure (Found) Quantiles - Q1 (Yes) (18)']","['Cell Line Ancestry - Caucasian (41)', 'Cell Line - WTC11 (30)', 'Cell Line - IMR90 (19)', 'Cell Line Ancestry - Asian (28)', 'Cell Line - DF19-9-11T.H (16)', 'hiPSC Matrix Coating - Matrigel (163)', 'Cell Line - 201B7 (9)', 'Day of Insulin Addition - Known (177)', 'hiPSC Backbone Media - Embryonic Stem Cell (127)', 'Cell Line - PGP1 (11)', 'Wnt Induction - CHIR99021 (184)', 'Wnt Inhibitor Duration (days) - Rare (173)', 'hiPSC-CM Media Supplement - B27 (180)', 'Wnt Inhibitor - IWP (112)', 'Wnt Induction - BMP4 (74)', 'hiPSC Backbone Media - mTeSR (106)', 'Cell Line - BJ1 (7)', 'Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10)', 'Seeding Confluency 3D (%) - 85 to 89 (12)', 'Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9)', 'hiPSC-CM Media Supplement - Mercaptoethanol (10)', 'Cell Line - C25 (6)', 'Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10)', 'hiPSC-CM Media Supplement - Selenium (7)', 'Journal - Stem Cell Res (8)', 'Pharmacological Intervention - Thalidomide (3)', 'Pharmacological Intervention - Cardiotoxic Agents (3)', 'Differentiation Purity Assessment - Flow Cytometry cTnI+ (3)']","['Cell Line Ancestry - Asian (28)', 'Cell Line - WTC11 (30)', 'Cell Line - DF19-9-11T.H (16)', 'Wnt Induction - CHIR99021 (184)', 'Cell Line - PGP1 (11)', '3D Tissue Media - RPMI-1640 (72)', 'Day of Insulin Addition - Known (177)', 'Wnt Inhibitor - IWP (112)', 'hiPSC Matrix Coating - Matrigel (163)', 'Purification Protocol - Glucose and Lactate (85)', 'Wnt Inhibitor Duration (days) Quantiles - Q2 (>1 and ≤2) (156)', 'hiPSC Backbone Media - Embryonic Stem Cell (127)', 'hiPSC Backbone Media - mTeSR (106)', 'Wnt Inhibitor Duration (days) - Rare (173)', 'hiPSC-CM Media Supplement - B27 (180)', 'hiPSC-CM Purification Duration (days) Quantiles - Q2 (>1 and ≤4) (61)', 'Insulin Start Day - 9 (10)', 'Cell Line - BJ1 (7)', 'Cell Line Ancestry - Caucasian (41)', 'hiPSC-CM Purification Duration (days) - 4 days (29)', 'Calcium Handling Analysis Method - Genetic (23)', 'Insulin Withdrawal Duration (days) - 4 days (18)', 'Publication Year - 2022 (20)', '3D CM Ratio (CM-EC-SC) Quantiles - Q2 (>75 and ≤91) (28)', 'Pharmacological Intervention - Thalidomide (3)', 'hiPSC-CM Media Supplement - Mercaptoethanol (10)', 'Insulin Withdrawal Duration (days) Quantiles - Q2 (>2 and ≤4) (25)', 'Journal - Nat Biomed Eng (5)', 'Day of Insulin Addition - not 22 (12)']","['Cell Line - IMR90 (19)', 'Cell Line Ancestry - Caucasian (41)', 'Cell Line - 201B7 (9)', 'Wnt Induction - BMP4 (74)', 'Seeding Confluency 2D (%) - Rare (13)', 'Wnt Induction Duration (days) Quantiles - Q1 (>2 and ≤5) (61)', 'Wnt Induction - Activin A (80)', 'Seeding Confluency (%) - Rare (43)', 'Cell Line - SCVI-273 (8)', 'Number of Cell Lines - 2 (50)', 'Journal - Stem Cell Res (8)', 'Pharmacological Intervention - Carbamylcholine (6)', 'Cell Line - 201B6 (3)', 'Insulin Start Day - 5 (14)', 'Wnt Induction - bFGF (45)', 'Insulin Start Day - 4 (11)', 'Wnt Induction - Wnt3a (3)', '3D Stromal Cell Source - hiPSC-MuralC (3)', '3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27)', 'hiPSC Backbone Media - DMEM (10)', 'hiPSC-CM Media Supplement - Lipids (9)', 'hiPSC Backbone Media - Conditioned (12)', 'hiPSC-CM Media Supplement - GlutaMax (8)', 'Pharmacological Intervention - Thalidomide (3)', 'hiPSC-CM Media Supplement - L-glutamine (19)', 'Contractile Analysis Method - Force Transducer (27)', 'Metabolic Component - Ascorbic Acid (3)', 'Wnt Induction Duration (days) - 4 days (15)', 'Metabolic Component - Rare (4)', 'Metabolic Component - KOSR (3)', 'Journal - Stem Cells Int (3)', 'Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10)']","['Cell Line Sex - Both (118)', 'Cell Line - PGP1 (11)', 'Cell Line Sex - Female (40)', 'Cell Line - 201B7 (9)', 'Seeding Confluency (%) - Rare (43)', 'hiPSC Backbone Media - mTeSR (106)', 'Cell Line - C25 (6)', '3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27)', 'Wnt Induction - Activin A (80)', 'Wnt Induction Duration (days) Quantiles - Q1 (>2 and ≤5) (61)', 'Cell Line Sex - Male (64)', 'Publication Year - 2018 (45)', 'hiPSC-CM Purification Duration (days) Quantiles - Q2 (>1 and ≤4) (61)', 'Wnt Induction - bFGF (45)', 'Wnt Induction - BMP4 (74)', 'Cell Line - 201B6 (3)', 'Wnt Induction - Wnt3a (3)', 'Disease Modelling - Hypertrophic Cardiomyopathy (6)', 'hiPSC-CM Media Supplement - Polyvinylalchohol (6)', 'hiPSC-CM Media Supplement - Nonessential Amino Acids (8)', 'Wnt Induction Duration (days) - 4 days (15)', 'Seeding Confluency 3D (%) - Rare (26)', '3D Stromal Cell Source - hiPSC-MuralC (3)', '3D Endothelial Cell Source - hiPSC-EndothelialC (16)', 'Differentiation Purity Assessment - Flow Cytometry cTnI+ (3)', 'Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5)']","['Cell Line - WTC11 (30)', 'Cell Line Sex - Male (64)', 'Cell Line Sex - Both (118)', 'Calcium Handling Analysis Method - Genetic (23)', '3D Tissue Media - RPMI-1640 (72)', 'Publication Year - 2022 (20)', 'hiPSC Backbone Media - Essential 8 (82)', '3D Estimated Cell Density (mil cells/mL) Quantiles - Q4 (>0.47 and ≤5) (25)', 'hiPSC Matrix Coating - Matrigel (163)', 'Day of Insulin Addition - not 20 (15)', 'Differentiation Purity (%) Quantiles - Q4 (>79 and ≤85) (40)', 'hiPSC-CM Purification Duration (days) - 4 days (29)', 'Journal - Tissue Eng Part A (4)', 'Day of Insulin Addition - not 21 (14)', 'Day of Insulin Addition - not 22 (12)', 'Insulin Withdrawal Duration (days) - 4 days (18)', 'Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9)', 'Day of Insulin Addition - not 24 (9)', 'Pharmacological Intervention - Cardiotoxic Agents (3)', 'Journal - Nat Biomed Eng (5)', '3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10)']","['Coating for Replating - Laminin (5)', 'Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5)', 'Electrophysiology Analysis Method - Genetic (3)', 'Cell Line - Rare (132)', '2D Surface - ECM-coated (115)', 'Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10)', 'Coating for Replating - Gelatin (43)', 'Purification Protocol - Cell Sorting (7)', 'Electrophysiology Analysis Method - Patch Clamp (59)', 'Cell Line - iCell (47)', '3D Tissue Media - RPMI-1640 (72)', 'Contractile Analysis Method - Deflection (39)', 'Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8)', 'Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6)', 'hiPSC Matrix Coating - Geltrex (33)', 'Journal - Am J Physiol Heart Circ Physiol (4)', 'MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4)', 'Journal - Circulation (11)', 'Journal - Biosens Bioelectron (4)', '3D Platform - Matrigel (33)', 'Number of Cell Lines - 2 (50)', 'hiPSC-CM Purification Duration (days) - 4 days (29)', 'TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4)', 'hiPSC-CM Maturation Media - Cor.4U Complete (6)', 'Number of Cell Lines - 4 (11)', 'MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4)', 'Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8)', 'Journal - Stem Cell Res Ther (3)', 'Differentiation Purity Assessment - Flow Cytometry SIRPA+ (4)', 'Insulin Start Day - 2 (4)', 'Journal - Sci Transl Med (3)', 'Journal - Sci Adv (3)']","['Coating for Replating - Laminin (5)', 'Electrophysiology Analysis Method - Genetic (3)', 'Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5)', 'Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6)', 'Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8)', 'Journal - Am J Physiol Heart Circ Physiol (4)', 'Insulin Start Day - 11 (3)', 'MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4)', 'Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9)', 'hiPSC-CM Purification Duration (days) - 4 days (29)', 'Journal - Circulation (11)', 'MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4)', 'Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10)', 'Maturation Strategy - ECM (21)', 'Electrophysiology Analysis Method - Patch Clamp (59)', 'Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8)', 'TNNI3 Precentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4)', 'Journal - Sci Transl Med (3)', 'Pharmacological Intervention - Lidocaine (7)', 'hiPSC-CM Backbone Media - Rare (10)', 'Insulin Start Day - 9 (10)', 'Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18)', 'hiPSC-CM Backbone Media - Cor.4U Complete (6)', 'hiPSC-CM Purification Duration (days) - 3 days (13)', 'hiPSC-CM Maturation Media - Cor.4U Complete (6)', 'Maturation Strategy - Mechanical (36)', 'Differentiation Purity (%) Quantiles - Q4 (>79 and ≤85) (40)', 'Wnt Induction - Rare (4)', 'Cell Line - Rare (132)', 'Journal - Biosens Bioelectron (4)']","['Metabolic Component Category - Sugars and Carbohydrates (9)', 'Publication Year - 2024 (7)', 'Metabolic Analysis Method - Genetic (3)', 'Seeding Confluency 3D (%) - 90 to 94 (13)', 'Metabolic Component - B27 (3)', 'Maturation Strategy - Metabolic (33)', 'Pharmacological Intervention - Epinephrine (11)', 'Differentiation Purity Assessment - Rare (3)', 'Metabolic Component - Albumax (3)', 'Wnt Inhibitor Duration (days) - 6 days (4)', '3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24)', 'New Media for Maturation - DMEM (21)', 'Publication Year - 2022 (20)', 'hiPSC Backbone Media - mTeSR (106)', 'Metabolic Component - Ascorbic Acid (3)', 'Metabolic Component - Fatty Acid (13)', 'Journal - Rare (104)', 'Insulin Start Day - After 11 (7)', 'Contractile Analysis Method - Motion Tracking (93)', 'Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12)', 'Metabolic Component - KOSR (3)', 'Insulin Start Day - 9 (10)', 'Differentiation Purity Assessment - Flow Cytometry a-actinin+ (9)', 'hiPSC-CM Media Supplement - Mercaptoethanol (10)', 'Metabolic Component - Biotin (3)', 'Coating for Replating - Vitronectin (3)', '3D Endothelial Cell Source - Umbilical Vein EndothelialC (10)', 'MYL2 Precentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4)', 'Journal - Tissue Eng Part A (4)', 'Cell Line Sex - Male (64)']","['Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34)', '2D Surface - Micropatterned (27)', 'hiPSC Matrix Coating - MEF feeder cells (8)', 'Wnt Inhibitor - BMP4 (7)', 'Number of Cell Lines - 3 (29)', 'Insulin Start Day - 7 (85)', 'hiPSC-CM Purification Duration (days) - <3 days (31)', '3D Stromal Cell Source - Mesenchymal Stem Cell (12)', '3D Tissue Media - Iscove (5)', 'hiPSC-CM Purification Duration (days) Quantiles - Q2 (>1 and ≤4) (61)', 'Maturation Strategy - Mechanical (36)', 'Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8)', 'Pharmacological Intervention - Positive Inotropes (9)', 'Publication Year - 2015 (19)', 'Publication Year - 2024 (7)', '3D Platform - Collagen (38)', 'hiPSC Backbone Media - DMEM (10)', 'Differentiation Purity Assessment - Flow Cytometry cTnT+ (135)', 'Deduced Culture Strategy - 2D Only (183)', 'hiPSC-CM Maturation Media - RPMI-1640 (153)', '3D Estimated Cell Density (mil cells/mL) Quantiles - Q4 (>0.47 and ≤5) (25)', 'Coating for Replating - Fibronectin (32)', 'Journal - Cell Stem Cell (6)', '3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47)', 'Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11)', 'Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14)', '3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119)', 'Sacromere or Cellular Alignment Analysis - Yes (72)', '3D Tissue Media - Commercial Kit (21)', '3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28)']","['hiPSC-CM Purification Duration (days) - <3 days (31)', 'Insulin Start Day - 7 (85)', 'Cell Line - PGP1 (11)', 'Contractile Analysis Method - Traction Force Microscopy (9)', 'Journal - Circ Res (5)', 'Coating for Replating - Matrigel (65)', 'Journal - ACS Appl Mater Interfaces (4)', 'T-tubule Structure (Found) Quantiles - Q1 (Yes) (18)', 'hiPSC-CM Purification Duration (days) Quantiles - Q2 (>1 and ≤4) (61)', 'Journal - Nat Biomed Eng (5)', 'hiPSC-CM Backbone Media - iCell Maintenance (86)', 'Maturation Strategy - Cell Alignment (59)', 'Cell Line Ancestry - Caucasian (41)', 'Purification Protocol - Glucose and Lactate (85)', 'Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9)', 'Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13)', 'hiPSC-CM Maturation Media - iCell Maintenance (83)', 'Differentiation Purity (%) Quantiles - Q5 (>30 and ≤79) (32)', '3D Platform - 3D printed (9)', '2D Surface - Micropatterned (27)', 'Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14)', 'Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11)', 'Wnt Inhibitor Duration (days) - Rare (173)', 'Cell Line - BJ1 (7)', 'Journal - Circulation (11)', 'Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10)', 'Wnt Inhibitor - IWP (112)', 'Wnt Inhibitor - Wnt-C59 (30)', 'Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10)', 'Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9)', '3D Estimated Cell Density (mil cells/mL) Quantiles - Q4 (>0.47 and ≤5) (25)', 'Wnt Inhibitor - XAV939 (24)']","['Journal - Nat Commun (13)', '3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24)', '3D Stromal Cell Source - Human Fibroblast (38)', '3D Stromal Cell Source - Cardiac Fibroblast (32)', 'Number of Cell Lines - 2 (50)', '3D Tissue Media - Commercial Kit (21)', 'Journal - Biomaterials (16)', 'Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11)', 'Insulin Start Day - After 11 (7)', 'Differentiation Purity (%) Quantiles - Q1 (>95 and ≤99) (22)', 'Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10)', '3D Estimated Tissue Size (mm2) Quantiles - Q4 (>0.13 and ≤2) (31)', 'Differentiation Purity Assessment - Visual Inspection (6)', 'Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12)', '3D Platform - Matrigel (33)', '3D Tissue Media - Iscove (5)', '3D Platform - 3D printed (9)', '3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47)', 'New Media for Maturation - Rare (4)', 'Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10)', '3D Endothelial Cell Source - Umbilical Vein EndothelialC (10)', 'hiPSC Backbone Media - Conditioned (12)', 'Contractile Analysis Method - Deflection (39)', 'Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9)', 'Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18)', 'Gene Analysis Method - RNA (169)', 'Publication Year - 2017 (43)']","['Calcium Handling Analysis Method - Visual (104)', 'Electrophysiology Analysis Method - Microelectrode (31)', '3D Tissue Media - DMEM (53)', 'Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11)', 'Contractile Analysis Method - Motion Tracking (93)', 'Cell Coculture - Cardiomyocyte (157)', 'Electrophysiology Analysis Method - Optical Mapping (39)', '3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119)', 'Deduced Culture Strategy - 3D Only (157)', 'hiPSC Backbone Media - Essential 8 (82)', 'Publication Year - 2016 (32)', '3D Tissue Media - MEM-α (60)', 'Differentiation Purity (%) Quantiles - Q5 (>30 and ≤79) (32)', 'hiPSC-CM Purification Duration (days) - 5 days (6)', 'Contractile Analysis Method - Deflection (39)', 'Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10)', '3D Stromal Cell Source - Cardiac Fibroblast (32)', 'Coating for Replating - Fibronectin (32)', 'Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11)', 'Cell Line - iCell2 (8)', 'Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9)', 'Journal - Lab Chip (4)', 'hiPSC Matrix Coating - Geltrex (33)', 'Maturation Strategy - ECM (21)', 'Journal - Toxicological Sciences (4)', '3D Tissue Media - Growth Factor (12)', 'Purification Protocol - Cell Sorting (7)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10)', 'Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10)']","['Calcium Handling Analysis Method - Visual (104)', 'Electrophysiology Analysis Method - Microelectrode (31)', '3D Tissue Media - DMEM (53)', 'Contractile Analysis Method - Motion Tracking (93)', 'Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11)', 'Electrophysiology Analysis Method - Optical Mapping (39)', '3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119)', 'Contractile Analysis Method - Deflection (39)', 'hiPSC Backbone Media - Essential 8 (82)', 'Cell Coculture - Cardiomyocyte (157)', '3D Tissue Media - MEM-α (60)', 'Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11)', 'Differentiation Purity (%) Quantiles - Q5 (>30 and ≤79) (32)', 'Publication Year - 2016 (32)', '3D Stromal Cell Source - Human Fibroblast (38)', 'Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6)', 'Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10)', '3D Tissue Media - Growth Factor (12)', 'Journal - Sci Rep (24)', 'Maturation Strategy - ECM (21)', 'Journal - Toxicological Sciences (4)', '3D Platform - Gelatin (6)', 'Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11)', 'Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12)', 'Purification Protocol - Cell Sorting (7)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10)', 'New Media for Maturation - Rare (4)']","['Calcium Handling Analysis Method - Visual (104)', 'Contractile Analysis Method - Motion Tracking (93)', 'Electrophysiology Analysis Method - Microelectrode (31)', 'Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11)', '3D Tissue Media - DMEM (53)', 'Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11)', 'Electrophysiology Analysis Method - Optical Mapping (39)', 'Contractile Analysis Method - Deflection (39)', 'Differentiation Purity (%) Quantiles - Q5 (>30 and ≤79) (32)', 'Cell Coculture - Cardiomyocyte (157)', '3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119)', '3D Tissue Media - MEM-α (60)', 'Deduced Culture Strategy - 3D Only (157)', 'Publication Year - 2016 (32)', 'hiPSC Backbone Media - Essential 8 (82)', 'Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10)', 'Electron Imaging - Scanning (22)', 'Journal - Sci Rep (24)', 'hiPSC Matrix Coating - Geltrex (33)', 'Calcium Handling Analysis Method - Genetic (23)', '3D Stromal Cell Source - Cardiac Fibroblast (32)', '3D Stromal Cell Source - Human Fibroblast (38)', '3D Tissue Media - Growth Factor (12)', 'Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12)', 'Maturation Strategy - ECM (21)', 'Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10)', 'Gene Analysis Method - Rare (5)', 'Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9)', '3D Platform - Gelatin (6)', 'Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11)', 'Purification Protocol - Cell Sorting (7)', 'New Media for Maturation - Rare (4)', 'Journal - Toxicological Sciences (4)', 'Cell Line - Cellapy (4)']","['Electrophysiology Analysis Method - Microelectrode (31)', '2D Surface - Microelectrode Array (9)', 'Cell Line - iCell (47)', 'Cell Line - Cor.4U (16)', 'Electrophysiology Analysis Method - Patch Clamp (59)', 'hiPSC-CM Media Supplement - iCell Maintenance Medium (41)', 'Coating for Replating - Gelatin (43)', '3D Platform - Extracellular Scaffold (18)', 'Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10)', 'Wnt Inhibitor Duration (days) Quantiles - Q1 (>2 and ≤9) (58)', 'Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7)', 'Disease Modelling - Arrhythmic (15)', 'Number of Cell Lines - >5 (9)', 'Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34)', 'Maturation Strategy - Electrical (39)', 'hiPSC-CM Backbone Media - Cor.4U Complete (6)', 'Maturation Strategy - ECM (21)', '3D Platform - Nanotechnology (3)', 'Journal - Toxicological Sciences (4)', 'Publication Year - 2017 (43)', 'Journal - Biomaterials (16)', 'Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12)', 'Publication Year - 2016 (32)', 'Number of Cell Lines - 3 (29)', 'Publication Year - 2018 (45)', 'Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11)', 'Seeding Confluency 3D (%) - 85 to 89 (12)', 'Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12)', 'Insulin Start Day - 11 (3)', 'hiPSC-CM Media Supplement - Lipid Mix (5)', 'Journal - Int J Mol Sci (3)', 'hiPSC-CM Media Supplement - Selenium (7)', 'Cell Line - 253G1 (10)']","['Electrophysiology Analysis Method - Microelectrode (31)', 'Journal - Toxicological Sciences (4)', 'Cell Line - iCell (47)', 'Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7)', 'hiPSC-CM Media Supplement - iCell Maintenance Medium (41)', 'Number of Cell Lines - 4 (11)', '2D Surface - Decellularized ECM (3)', '3D Platform - Scaffold Free (43)', 'hiPSC-CM Maturation Media - iCell Maintenance (83)', 'hiPSC-CM Maturation Media - Rare (9)', 'Cell Line - Cellapy (4)', 'Contractile Analysis Method - Motion Tracking (93)', 'Electron Imaging - Scanning (22)', 'Calcium Handling Analysis Method - Visual (104)', 'Journal - Nat Commun (13)', 'hiPSC-CM Backbone Media - iCell Maintenance (86)', '3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28)', 'Electrophysiology Analysis Method - Optical Mapping (39)', 'Coating for Replating - Gelatin (43)', 'Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14)', 'Number of Cell Lines - 3 (29)', 'Cell Line - Cor.4U (16)', 'Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10)', 'hiPSC-CM Backbone Media - Rare (10)', 'Cell Line - iCell2 (8)', 'Publication Year - 2017 (43)', 'Number of Cell Lines - >5 (9)', 'Journal - Sci Rep (24)', 'Differentiation Purity Assessment - Visual Inspection (6)', 'Cell Line Ancestry - Asian (28)', '2D Surface - Microelectrode Array (9)', 'Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11)', 'Journal - Front Cell Dev Biol (3)', '3D Stromal Cell Source - hiPSC-CardiacF (8)', 'Journal - Circ Res (5)']","['Electrophysiology Analysis Method - Microelectrode (31)', 'Journal - Toxicological Sciences (4)', 'Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7)', 'Cell Line - Cellapy (4)', 'Calcium Handling Analysis Method - Visual (104)', 'hiPSC-CM Media Supplement - iCell Maintenance Medium (41)', '3D Platform - Scaffold Free (43)', 'Cell Line - iCell (47)', '2D Surface - Decellularized ECM (3)', 'Journal - Nat Commun (13)', 'Number of Cell Lines - 4 (11)', 'hiPSC-CM Maturation Media - Rare (9)', 'Electron Imaging - Scanning (22)', 'Cell Line Ancestry - Caucasian (41)', 'hiPSC-CM Backbone Media - iCell Maintenance (86)', 'Contractile Analysis Method - Motion Tracking (93)', 'Publication Year - 2017 (43)', '3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28)', 'Number of Cell Lines - 3 (29)', 'Journal - Sci Rep (24)', 'hiPSC-CM Maturation Media - iCell Maintenance (83)', 'Number of Cell Lines - >5 (9)', 'hiPSC-CM Backbone Media - Rare (10)', 'Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10)', 'Coating for Replating - Gelatin (43)', 'Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14)', 'Cell Line - Cor.4U (16)', 'Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14)', 'Cell Line - iCell2 (8)', 'Cell Line Ancestry - Asian (28)', '2D Surface - Microelectrode Array (9)', 'Journal - Front Cell Dev Biol (3)', 'Journal - Circ Res (5)', 'Differentiation Purity Assessment - Visual Inspection (6)']","['Electrophysiology Analysis Method - Microelectrode (31)', 'Journal - Toxicological Sciences (4)', 'Cell Line - Cellapy (4)', 'Number of Cell Lines - 4 (11)', 'hiPSC-CM Media Supplement - iCell Maintenance Medium (41)', 'Cell Line - iCell (47)', 'Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7)', 'Cell Line - Cor.4U (16)', '3D Platform - Scaffold Free (43)', 'hiPSC-CM Maturation Media - iCell Maintenance (83)', '2D Surface - Decellularized ECM (3)', 'Number of Cell Lines - 3 (29)', 'Cell Line - WTC11 (30)', 'hiPSC-CM Backbone Media - iCell Maintenance (86)', 'Calcium Handling Analysis Method - Visual (104)', 'Cell Line Ancestry - Asian (28)', 'Publication Year - 2017 (43)', 'Electron Imaging - Scanning (22)', 'Cell Line - iCell2 (8)', 'Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14)', 'Journal - Sci Rep (24)', 'Coating for Replating - Gelatin (43)', 'hiPSC-CM Maturation Media - Rare (9)', 'hiPSC-CM Backbone Media - Rare (10)', 'Cell Line Ancestry - Caucasian (41)', '2D Surface - Microelectrode Array (9)', '3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47)', 'Journal - Nat Commun (13)', 'Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14)']","['Journal - Toxicological Sciences (4)', 'Wnt Inhibitor - KY02111 (7)', 'Journal - Int J Mol Sci (3)', 'Wnt Inhibitor - Others (9)', 'hiPSC-CM Maturation Media - iCell Maintenance (83)', 'Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7)', 'Journal - Rare (104)', '3D Stromal Cell Source - Cardiac Fibroblast (32)', 'Seeding Confluency 2D (%) - 80 to 84 (5)', 'Maturation Strategy - ECM (21)', 'Number of Cell Lines - 4 (11)', 'Seeding Confluency (%) - 80 to 84 (12)', '3D Platform - Extracellular Scaffold (18)', '3D Stromal Cell Source - Human Fibroblast (38)', 'Journal - Sci Rep (24)', 'Seeding Confluency 3D (%) - 90 to 94 (13)', 'New Media for Maturation - Rare (4)', 'Electrophysiology Analysis Method - Patch Clamp (59)', 'Number of Cell Lines - 3 (29)', 'Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6)', 'Electrophysiology Analysis Method - Microelectrode (31)', 'Journal - Cell Rep (6)', 'hiPSC-CM Backbone Media - iCell Maintenance (86)', 'hiPSC-CM Media Supplement - iCell Maintenance Medium (41)', 'Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10)', 'Cell Line - Cellapy (4)', '2D Surface - ECM-coated (115)', 'Number of Cell Lines - >5 (9)', 'hiPSC-CM Media Supplement - GlutaMax (8)', 'hiPSC-CM Maturation Media - Cor.4U Complete (6)', 'Coating for Replating - Rare (6)', 'hiPSC-CM Media Supplement - Nonessential Amino Acids (8)', 'hiPSC-CM Media Supplement - HEPES (16)', 'Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12)', 'Coating for Replating - Synthemax (3)', '2D Surface - Decellularized ECM (3)', 'Publication Year - 2017 (43)']","['Electrophysiology Analysis Method - Microelectrode (31)', 'Maturation Strategy - Electrical (39)', 'Wnt Inhibitor Duration (days) Quantiles - Q1 (>2 and ≤9) (58)', 'Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10)', 'Publication Year - 2016 (32)', 'Cell Line - Cor.4U (16)', 'Publication Year - Late-2010s (196)', '3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74)', '2D Surface - Microelectrode Array (9)', 'Journal - Int J Mol Sci (3)', '3D Estimated Cell Density (mil cells/mL) Quantiles - Q4 (>0.47 and ≤5) (25)', 'Seeding Confluency 3D (%) - 85 to 89 (12)', 'Electron Imaging - Scanning (22)', 'Electron Imaging - Transmission (62)', 'Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9)', 'Wnt Inhibitor Duration (days) - 4 days (19)', 'Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12)', '2D Surface - Electrospun (13)', 'Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34)', 'Cell Line - iCell (47)', 'hiPSC-CM Media Supplement - L-glutamine (19)', 'Cell Line - 253G1 (10)', '3D Platform - Extracellular Scaffold (18)', 'Wnt Inhibitor - XAV939 (24)', 'Wnt Induction Duration (days) - 5 days (8)', '3D Platform - Nanotechnology (3)', 'Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10)']","['Electrophysiology Analysis Method - Microelectrode (31)', 'Cell Line - iCell (47)', 'Number of Cell Lines - 3 (29)', 'Calcium Handling Analysis Method - Visual (104)', 'Wnt Induction Duration (days) Quantiles - Q3 (>1 and ≤1) (186)', 'Journal - Biomaterials (16)', 'Electrophysiology Analysis Method - Optical Mapping (39)', 'hiPSC-CM Backbone Media - iCell Maintenance (86)', 'Journal - Toxicological Sciences (4)', 'Number of Cell Lines - 4 (11)', 'Journal - Nat Commun (13)', 'hiPSC-CM Maturation Media - iCell Maintenance (83)', 'Differentiation Purity Assessment - Flow Cytometry cTnI+ (3)', '3D Platform - Polyethylene Glycol (8)', '3D Tissue Media - Commercial Kit (21)', 'Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12)', 'Gene Analysis Method - RNA (169)', 'Disease Modelling - Arrhythmic (15)', 'Differentiation Purity (%) Quantiles - Q5 (>30 and ≤79) (32)', 'Publication Year - 2021 (43)', 'Differentiation Purity Assessment - Flow Cytometry a-actinin+ (9)', 'Cell Line - 253G1 (10)', 'Disease Modelling - Fibrotic (4)', '2D Surface - ECM-coated (115)', 'Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12)', 'Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11)', 'hiPSC-CM Purification Duration (days) - 5 days (6)', 'Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7)', 'Journal - Cell Rep (6)', 'Journal - Sci Rep (24)', 'Number of Cell Lines - 2 (50)']","['Journal - Sci Rep (24)', 'Cell Line - iCell (47)', 'hiPSC-CM Maturation Media - iCell Maintenance (83)', 'hiPSC-CM Media Supplement - iCell Maintenance Medium (41)', 'Journal - Toxicological Sciences (4)', '3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31)', 'Coating for Replating - Matrigel (65)', 'hiPSC-CM Backbone Media - iCell Maintenance (86)', '3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5)', '3D Platform - Scaffold Free (43)', '3D Tissue Media - Rare (13)', 'Journal - Nat Commun (13)', 'Contractile Analysis Method - Deflection (39)', 'Insulin Withdrawal Duration (days) - 8 days (3)', 'hiPSC-CM Purification Duration (days) - 8 days (4)', 'Publication Year - Late-2010s (196)', 'Publication Year - 2020 (51)', '2D Surface - ECM-coated (115)', 'Cell Coculture - Endothelial Cell (35)', '3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24)', 'T-tubule Structure (Found) Quantiles - Q1 (Yes) (18)', 'Insulin Start Day - 0 (7)', '3D Tissue Media - Commercial Kit (21)', 'Journal - Biomaterials (16)', 'Coating for Replating - Gelatin (43)', 'Contractile Analysis Method - Motion Tracking (93)', 'hiPSC-CM Purification Duration (days) - >9 days (5)', 'Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108)', 'Journal - Tissue Eng Part C Methods (6)', 'Maturation Strategy - Mechanical (36)', 'Cell Line - Cellapy (4)', 'Maturation Strategy - Other Cells (80)', 'Journal - Sci Transl Med (3)', '3D Estimated Tissue Size (mm2) Quantiles - Q4 (>0.13 and ≤2) (31)', 'Purification Protocol - Antibiotic (4)', '3D Endothelial Cell Source - Rare (3)']","['Journal - Sci Rep (24)', 'hiPSC-CM Maturation Media - iCell Maintenance (83)', '3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31)', 'Coating for Replating - Matrigel (65)', 'Journal - Toxicological Sciences (4)', 'Publication Year - Late-2010s (196)', 'Cell Line - iCell (47)', 'hiPSC-CM Backbone Media - iCell Maintenance (86)', 'hiPSC-CM Purification Duration (days) - 8 days (4)', '2D Surface - ECM-coated (115)', 'hiPSC-CM Media Supplement - iCell Maintenance Medium (41)', '3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5)', 'Publication Year - 2016 (32)', '3D Tissue Media - Commercial Kit (21)', 'Cell Coculture - Endothelial Cell (35)', 'Journal - Nat Commun (13)', 'Maturation Strategy - Other Cells (80)', 'Insulin Withdrawal Duration (days) - 8 days (3)', '3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24)', '3D Platform - Scaffold Free (43)', 'Publication Year - 2020 (51)', 'T-tubule Structure (Found) Quantiles - Q1 (Yes) (18)', 'Wnt Inhibitor - VEGF (3)', 'Contractile Analysis Method - Motion Tracking (93)', 'Journal - Sci Transl Med (3)', 'Insulin Start Day - 0 (7)', 'hiPSC-CM Purification Duration (days) - >9 days (5)', 'Journal - Tissue Eng Part C Methods (6)', '3D Endothelial Cell Source - Rare (3)', 'Coating for Replating - Gelatin (43)', 'Day of Insulin Addition - not 19 (9)', 'Purification Protocol - Antibiotic (4)']","['Electrophysiology Analysis Method - Microelectrode (31)', 'Cell Line - iCell (47)', 'Journal - Toxicological Sciences (4)', 'Journal - Biomaterials (16)', 'Wnt Induction Duration (days) Quantiles - Q3 (>1 and ≤1) (186)', 'Calcium Handling Analysis Method - Visual (104)', 'Number of Cell Lines - 4 (11)', 'Number of Cell Lines - 3 (29)', 'hiPSC-CM Backbone Media - iCell Maintenance (86)', 'Electrophysiology Analysis Method - Optical Mapping (39)', 'Publication Year - 2021 (43)', 'Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12)', 'Publication Year - 2016 (32)', 'Journal - Nat Commun (13)', 'hiPSC-CM Maturation Media - iCell Maintenance (83)', '2D Surface - ECM-coated (115)', '3D Platform - Polyethylene Glycol (8)', 'Coating for Replating - Rare (6)', 'Differentiation Purity (%) Quantiles - Q5 (>30 and ≤79) (32)', 'Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5)', 'hiPSC-CM Media Supplement - iCell Maintenance Medium (41)', 'Differentiation Purity Assessment - Flow Cytometry a-actinin+ (9)', 'Coating for Replating - Gelatin (43)', 'Journal - Sci Rep (24)', 'Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11)', 'hiPSC-CM Purification Duration (days) - 5 days (6)', 'Journal - Cell Rep (6)', 'Wnt Inhibitor - BMP4 (7)', 'Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7)', '3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5)', 'Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34)']","['Number of Cell Lines - 3 (29)', 'Journal - Toxicological Sciences (4)', 'hiPSC-CM Media Supplement - iCell Maintenance Medium (41)', 'Wnt Inhibitor Duration (days) - >6 days (12)', 'Cell Line - Cor.4U (16)', 'Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11)', 'hiPSC-CM Purification Duration (days) - 3 days (13)', 'Maturation Strategy - ECM (21)', 'Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108)', 'Cell Line - iCell (47)', 'Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9)', 'Insulin Start Day - 6 (20)', 'Publication Year - 2019 (57)', 'Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12)', 'Journal - Sci Rep (24)', 'Coating for Replating - Gelatin (43)', 'Wnt Inhibitor - DS-I-7 (9)', 'Cell Line - iCell2 (8)', 'Journal - Cell Stem Cell (6)', 'hiPSC-CM Media Supplement - Lipid Mix (5)', 'Insulin Start Day - 4 (11)', '3D Estimated Tissue Size (mm2) Quantiles - Q2 (>9.12 and ≤26.2) (26)', '2D Surface - ECM-coated (115)', 'Wnt Inhibitor - KY02111 (7)', 'Journal - J Tissue Eng Regen Med (3)', 'Insulin Withdrawal Duration (days) - 3 days (6)', 'Insulin Withdrawal Duration (days) Quantiles - Q2 (>2 and ≤4) (25)', 'Journal - Cell Rep (6)', 'Purification Protocol - Metabolic (8)', 'Publication Year - Post 2020 (122)', 'Differentiation Purity Assessment - IHC a-actinin (8)', '2D Surface - Microelectrode Array (9)', 'Electrophysiology Analysis Method - Patch Clamp (59)', 'Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12)', 'hiPSC-CM Maturation Media - Commercial Kit (27)']","['Cell Line - iCell2 (8)', 'hiPSC-CM Maturation Media - iCell Maintenance (83)', 'Journal - Toxicological Sciences (4)', 'Journal - Nat Commun (13)', 'Electrophysiology Analysis Method - Microelectrode (31)', 'Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108)', 'Journal - Lab Chip (4)', 'Calcium Handling Analysis Method - Visual (104)', 'hiPSC-CM Backbone Media - iCell Maintenance (86)', 'Publication Year - 2017 (43)', '2D Surface - ECM-coated (115)', 'hiPSC-CM Media Supplement - iCell Maintenance Medium (41)', 'hiPSC-CM Purification Duration (days) - 5 days (6)', 'Disease Modelling - Ischemic Infarction (9)', 'Coating for Replating - Matrigel (65)', '3D Tissue Media - Rare (13)', 'Cell Coculture - Endothelial Cell (35)', 'Electrophysiology Analysis Method - Optical Mapping (39)', '3D Tissue Media - Commercial Kit (21)', '3D Platform - Extracellular Scaffold (18)', 'Journal - Rare (104)', 'Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10)', '3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5)', 'Publication Year - Post 2020 (122)', '3D Stromal Cell Source - Cardiac Fibroblast (32)', '2D Surface - Microelectrode Array (9)', 'Publication Year - 2020 (51)', 'Differentiation Purity Assessment - Flow Cytometry a-actinin+ (9)', 'Differentiation Purity Assessment - Flow Cytometry SIRPA+ (4)', 'Wnt Inhibitor - Others (9)', 'Deduced Culture Strategy - 2D Only (183)', '2D Surface - Decellularized ECM (3)']","['Cell Line - iCell2 (8)', 'Journal - Toxicological Sciences (4)', 'hiPSC-CM Maturation Media - iCell Maintenance (83)', 'Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108)', 'Electrophysiology Analysis Method - Microelectrode (31)', 'Journal - Lab Chip (4)', 'hiPSC-CM Backbone Media - iCell Maintenance (86)', 'Journal - Nat Commun (13)', 'Publication Year - 2017 (43)', 'Disease Modelling - Ischemic Infarction (9)', 'Calcium Handling Analysis Method - Visual (104)', 'Cell Line - Rare (132)', '3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5)', 'hiPSC-CM Purification Duration (days) - 5 days (6)', 'Coating for Replating - Matrigel (65)', '3D Tissue Media - Rare (13)', '2D Surface - ECM-coated (115)', 'hiPSC-CM Media Supplement - iCell Maintenance Medium (41)', 'Cell Line - iCell (47)', '3D Estimated Cell Density (mil cells/mL) Quantiles - Q4 (>0.47 and ≤5) (25)', '3D Platform - Extracellular Scaffold (18)', '3D Stromal Cell Source - Cardiac Fibroblast (32)', 'Publication Year - Late-2010s (196)', '2D Surface - Microelectrode Array (9)', '2D Surface - Decellularized ECM (3)', 'Electrophysiology Analysis Method - Optical Mapping (39)', 'Publication Year - 2019 (57)', 'Publication Year - 2016 (32)', 'Wnt Inhibitor - Others (9)']","['Cell Line - iCell (47)', 'Number of Cell Lines - 3 (29)', 'Disease Modelling - Arrhythmic (15)', 'Journal - Cell Rep (6)', 'Cell Line - Cor.4U (16)', 'Differentiation Purity Assessment - Flow Cytometry cTnI+ (3)', 'Electrophysiology Analysis Method - Microelectrode (31)', 'Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108)', 'Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12)', '2D Surface - Microelectrode Array (9)', 'hiPSC-CM Maturation Media - iCell Maintenance (83)', 'hiPSC-CM Media Supplement - iCell Maintenance Medium (41)', 'hiPSC-CM Media Supplement - Rare (5)', 'Maturation Strategy - ECM (21)', 'Coating for Replating - Gelatin (43)', 'Coating for Replating - Geltrex (10)', 'Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12)', 'Electrophysiology Analysis Method - Patch Clamp (59)', 'Journal - Toxicological Sciences (4)', 'Disease Modelling - Genetic Disorders (18)', 'Number of Cell Lines - 4 (11)', 'Electron Imaging - Scanning (22)', 'hiPSC-CM Maturation Media - Cor.4U Complete (6)', 'hiPSC-CM Backbone Media - iCell Maintenance (86)', 'Coating for Replating - Rare (6)', 'Calcium Handling Analysis Method - Visual (104)', 'Number of Cell Lines - >5 (9)', 'Electrophysiology Analysis Method - Genetic (3)', 'Purification Protocol - Metabolic (8)', '2D Surface - ECM-coated (115)', 'Cell Line Ancestry - Caucasian (41)', 'Wnt Induction - Rare (4)', 'Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13)']","['Cell Line - Cor.4U (16)', 'Journal - Cell Rep (6)', 'Number of Cell Lines - 3 (29)', 'Disease Modelling - Arrhythmic (15)', 'Journal - Acta Biomater (10)', 'Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13)', 'Number of Cell Lines - >5 (9)', 'Journal - Toxicological Sciences (4)', 'Cell Line - iCell (47)', 'Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12)', 'Journal - Int J Mol Sci (3)', 'Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7)', 'Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9)', 'Coating for Replating - Gelatin (43)', 'Publication Year - 2017 (43)', 'Number of Cell Lines - 4 (11)', 'Contractile Analysis Method - Traction Force Microscopy (9)', 'Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5)', 'Maturation Strategy - Electrical (39)', 'hiPSC-CM Media Supplement - iCell Maintenance Medium (41)', '3D Tissue Media - Rare (13)', 'hiPSC-CM Maturation Media - Cor.4U Complete (6)', 'hiPSC-CM Backbone Media - Cor.4U Complete (6)', 'hiPSC-CM Maturation Media - iCell Maintenance (83)']","['Journal - Toxicological Sciences (4)', 'Cell Line - iCell (47)', 'Number of Cell Lines - 4 (11)', 'Gene Analysis Method - RNA (169)', '3D Tissue Media - Commercial Kit (21)', 'Cell Line Ancestry - Caucasian (41)', 'Publication Year - 2019 (57)', 'Journal - Sci Rep (24)', 'hiPSC-CM Media Supplement - iCell Maintenance Medium (41)', '2D Surface - Decellularized ECM (3)', 'Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5)', 'hiPSC Matrix Coating - Geltrex (33)', 'Insulin Start Day - 6 (20)', 'hiPSC-CM Media Supplement - Nonessential Amino Acids (8)', 'Publication Year - 2017 (43)', 'Number of Cell Lines - 2 (50)', '2D Surface - Microelectrode Array (9)', 'hiPSC-CM Purification Duration (days) - <3 days (31)', 'Cell Line - Cor.4U (16)', '3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24)', 'Coating for Replating - Gelatin (43)', '3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5)', 'Cell Line - iCell2 (8)', 'Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5)']","['Journal - Nat Commun (13)', 'Journal - Toxicological Sciences (4)', 'Wnt Inhibitor Duration (days) - >6 days (12)', 'Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10)', 'Electrophysiology Analysis Method - Optical Mapping (39)', 'Coating for Replating - Matrigel (65)', 'Cell Line - iCell (47)', '3D Platform - Fibrin (50)', '3D Stromal Cell Source - Human Fibroblast (38)', 'Electrophysiology Analysis Method - Microelectrode (31)', 'Contractile Analysis Method - Deflection (39)', 'hiPSC-CM Media Supplement - iCell Maintenance Medium (41)', 'hiPSC-CM Backbone Media - iCell Maintenance (86)', 'Calcium Handling Analysis Method - Visual (104)', '3D Tissue Media - Commercial Kit (21)', 'Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108)', '3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24)', '3D Platform - Matrigel (33)', 'Wnt Inhibitor - DS-I-7 (9)', '3D SC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤10) (29)', '3D Stromal Cell Source - Cardiac Fibroblast (32)', 'Publication Year - 2019 (57)', '3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5)', '3D Platform - Collagen (38)', 'Insulin Withdrawal Duration (days) - 3 days (6)', 'hiPSC-CM Purification Duration (days) - 3 days (13)', 'hiPSC-CM Backbone Media - Commercial CM Kit (12)', 'Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11)']","['Cell Line - iCell (47)', 'Journal - Toxicological Sciences (4)', 'Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12)', 'Disease Modelling - Arrhythmic (15)', 'hiPSC-CM Media Supplement - iCell Maintenance Medium (41)', 'Number of Cell Lines - 3 (29)', 'Maturation Strategy - ECM (21)', 'Cell Line - Cor.4U (16)', 'Number of Cell Lines - 4 (11)', 'Coating for Replating - Gelatin (43)', 'Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108)', 'Electrophysiology Analysis Method - Microelectrode (31)', 'hiPSC-CM Backbone Media - iCell Maintenance (86)', '3D Tissue Media - Iscove (5)', 'Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7)', 'Publication Year - 2017 (43)', 'Journal - Cell Rep (6)', 'Coating for Replating - Rare (6)', 'Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7)', '2D Surface - ECM-coated (115)', '3D Platform - Extracellular Scaffold (18)', 'Electrophysiology Analysis Method - Patch Clamp (59)', 'Disease Modelling - Fibrotic (4)', 'Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10)', 'Purification Protocol - Metabolic (8)', 'Wnt Induction - Rare (4)', 'Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12)']","['Cell Line - iCell (47)', 'hiPSC-CM Media Supplement - iCell Maintenance Medium (41)', 'hiPSC-CM Maturation Media - iCell Maintenance (83)', 'Coating for Replating - Gelatin (43)', 'Cell Line - Cor.4U (16)', 'Publication Year - 2020 (51)', 'Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7)', 'hiPSC-CM Backbone Media - iCell Maintenance (86)', '2D Surface - Microelectrode Array (9)', 'Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8)', 'Number of Cell Lines - 3 (29)', 'Journal - Toxicological Sciences (4)', 'Insulin Start Day - 11 (3)', 'Journal - Cell Rep (6)', '3D Platform - Nanotechnology (3)', 'Coating for Replating - Rare (6)', 'Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11)', 'Number of Cell Lines - >5 (9)', 'Differentiation Purity Assessment - Flow Cytometry cTnI+ (3)', 'Number of Cell Lines - 4 (11)', 'Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34)', 'Sacromere or Cellular Alignment Analysis - Yes (72)', 'Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8)', '2D Surface - ECM-coated (115)', 'Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9)', '3D Stromal Cell Source - hiPSC-CardiacF (8)', 'Electrophysiology Analysis Method - Microelectrode (31)', 'Differentiation Purity Assessment - IHC a-actinin (8)', 'Publication Year - Post 2020 (122)', '3D Tissue Media - iCell Maintenance (12)', 'Electrophysiology Analysis Method - Patch Clamp (59)', 'Maturation Strategy - Cell Alignment (59)']","['Number of Cell Lines - 3 (29)', 'hiPSC-CM Media Supplement - iCell Maintenance Medium (41)', 'Cell Line - Cor.4U (16)', 'Cell Line - iCell (47)', 'Journal - Toxicological Sciences (4)', 'Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7)', 'Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108)', 'Journal - Sci Rep (24)', 'Differentiation Purity Assessment - Visual Inspection (6)', 'Calcium Handling Analysis Method - Genetic (23)', 'Differentiation Purity Assessment - IHC a-actinin (8)', 'Wnt Inhibitor - KY02111 (7)', 'Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12)', 'Number of Cell Lines - >5 (9)', 'Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12)', 'Journal - Cell Rep (6)', 'Maturation Strategy - ECM (21)', 'Coating for Replating - Gelatin (43)', 'Coating for Replating - Rare (6)', 'hiPSC-CM Maturation Media - iCell Maintenance (83)', 'Disease Modelling - Arrhythmic (15)', 'hiPSC-CM Backbone Media - StemPro-34 (14)', '2D Surface - ECM-coated (115)', '2D Surface - Microelectrode Array (9)', 'Sacromere or Cellular Alignment Analysis - Yes (72)', 'Electrophysiology Analysis Method - Microelectrode (31)', 'Coating for Replating - Matrigel (65)', 'Number of Cell Lines - 4 (11)', 'Insulin Start Day - 4 (11)', 'New Media for Maturation - Rare (4)']","['Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12)', 'Cell Line - Cor.4U (16)', 'Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13)', 'Journal - Int J Mol Sci (3)', 'Number of Cell Lines - >5 (9)', 'Publication Year - 2017 (43)', 'hiPSC-CM Maturation Media - Cor.4U Complete (6)', '3D Tissue Media - Rare (13)', 'Number of Cell Lines - 4 (11)', 'Journal - Acta Biomater (10)', 'Disease Modelling - Arrhythmic (15)', 'Journal - Toxicological Sciences (4)', 'Cell Line - iCell (47)', '2D Surface - Nanotopography (6)', 'Calcium Handling Analysis Method - Genetic (23)', 'Number of Cell Lines - 3 (29)', 'Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108)', 'Number of Cell Lines - 2 (50)', 'Maturation Strategy - Electrical (39)', 'Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9)', 'hiPSC-CM Media Supplement - Albumin (28)', '3D Tissue Media - Iscove (5)', 'Disease Modelling - Hypertrophic Cardiomyopathy (6)', '2D Surface - Microelectrode Array (9)', '3D Platform - Matrigel (33)', 'Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5)', 'Contractile Analysis Method - Traction Force Microscopy (9)', 'Coating for Replating - Gelatin (43)', 'Electron Imaging - Transmission (62)', 'hiPSC-CM Backbone Media - Cor.4U Complete (6)', 'Calcium Handling Analysis Method - Visual (104)']","['Wnt Inhibitor Duration (days) - 4 days (19)', 'Insulin Start Day - 5 (14)', 'Seeding Confluency (%) - 85 to 89 (43)', 'Cell Line - SCVI-273 (8)', '3D Tissue Media - Iscove (5)', 'Seeding Confluency 2D (%) - 85 to 89 (26)', 'Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11)', 'Insulin Start Day - 3 (5)', 'hiPSC-CM Purification Duration (days) - 5 days (6)', 'Publication Year - 2018 (45)', 'Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13)', 'Cell Line - C25 (6)', 'Seeding Confluency 2D (%) - 95 to 100 (6)', 'Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11)', 'Wnt Inhibitor - bFGF (8)', 'Differentiation Purity Assessment - IHC cTnT (7)', 'Wnt Inhibitor - Wnt-C59 (30)', 'Journal - Cell Stem Cell (6)', 'Electrophysiology Analysis Method - Optical Mapping (39)', 'Wnt Inhibitor - Others (9)', 'Differentiation Purity Assessment - IHC a-actinin (8)', 'Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13)', 'Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6)', 'Journal - Acta Biomater (10)', '2D Surface - ECM-coated (115)', 'Differentiation Purity (%) Quantiles - Q4 (>79 and ≤85) (40)', 'Calcium Handling Analysis Method - Visual (104)']","['Differentiation Purity (%) Quantiles - Q5 (>30 and ≤79) (32)', '3D Platform - Polyethylene Glycol (8)', 'Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5)', 'Wnt Induction Duration (days) Quantiles - Q3 (>1 and ≤1) (186)', 'Calcium Handling Analysis Method - Visual (104)', 'Cell Line - 253G1 (10)', 'Cell Line - IMR90 (19)', 'Journal - Biomaterials (16)', 'Wnt Inhibitor - IWP (112)', 'Publication Year - 2016 (32)', 'hiPSC Matrix Coating - Vitronectin (10)', 'hiPSC-CM Purification Duration (days) - 5 days (6)', 'Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11)', 'Wnt Inhibitor - BMP4 (7)', 'Journal - Acta Biomater (10)', 'Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12)', 'Gene Analysis Method - RNA (169)', '2D Surface - Electrospun (13)', 'Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13)', 'Differentiation Purity Assessment - Flow Cytometry a-actinin+ (9)', 'Cell Line - DF19-9-11T.H (16)', 'Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13)', 'Insulin Start Day - 8 (15)', 'Number of Cell Lines - 4 (11)', '3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74)', '2D Surface - ECM-coated (115)', 'Publication Year - 2021 (43)', 'Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108)', 'Deduced Culture Strategy - 2D Only (183)', 'Journal - Stem Cell Res Ther (3)']","['Journal - Tissue Eng Part C Methods (6)', 'hiPSC-CM Media Supplement - HEPES (16)', 'Day of Insulin Addition - not 25 (3)', 'Day of Insulin Addition - not 9 (3)', '3D Tissue Media - Growth Factor (12)', 'Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8)', 'Publication Year - 2020 (51)', 'Journal - ACS Appl Mater Interfaces (4)', 'Journal - Am J Physiol Heart Circ Physiol (4)', 'Coating for Replating - Synthemax (3)', 'Seeding Confluency (%) - 95 to 100 (23)', 'hiPSC-CM Maturation Media - iCell Maintenance (83)', 'Seeding Confluency 2D (%) - 95 to 100 (6)', '3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24)', '3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119)', 'hiPSC-CM Media Supplement - GlutaMax (8)', 'hiPSC-CM Backbone Media - iCell Maintenance (86)', '3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74)', 'Insulin Start Day - 9 (10)', 'Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12)', 'Wnt Inhibitor - Others (9)', 'Insulin Withdrawal Duration (days) - 6 days (3)', 'Day of Insulin Addition - not 11 (5)', '3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27)', 'Insulin Start Day - 5 (14)', '3D Tissue Media - MEM-α (60)', 'Journal - Stem Cell Res Ther (3)']","['Electrophysiology Analysis Method - Microelectrode (31)', 'Cell Line - iCell (47)', 'Journal - Cell Rep (6)', 'Coating for Replating - Rare (6)', 'Journal - Sci Rep (24)', 'Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7)', 'Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34)', 'Number of Cell Lines - 3 (29)', 'Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11)', 'hiPSC-CM Maturation Media - iCell Maintenance (83)', '2D Surface - Hydrogel (17)', 'Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12)', 'Electrophysiology Analysis Method - Optical Mapping (39)', 'Cell Line - Cor.4U (16)', 'hiPSC-CM Media Supplement - iCell Maintenance Medium (41)', 'Wnt Inhibitor Duration (days) Quantiles - Q1 (>2 and ≤9) (58)', 'Publication Year - 2021 (43)', 'Maturation Strategy - Electrical (39)', 'Maturation Strategy - Elastomeric (33)', 'Coating for Replating - Gelatin (43)', 'Maturation Strategy - ECM (21)', 'Publication Year - 2016 (32)', 'Seeding Confluency 3D (%) - 90 to 94 (13)', 'hiPSC-CM Backbone Media - iCell Maintenance (86)', '2D Surface - ECM-coated (115)', 'Deduced Culture Strategy - 2D Only (183)']","['Metabolic Component - T3 (14)', 'Metabolic Component - Dexamethasone (7)', 'Insulin Start Day - 2 (4)', 'hiPSC-CM Maturation Media - F12 (10)', 'Wnt Inhibitor - Wnt-C59 (30)', 'Metabolic Component Category - Hormonal Stimulation (14)', 'Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10)', 'Wnt Inhibitor - bFGF (8)', 'Cell Line - Cellapy (4)', 'T-tubule Structure (Found) Quantiles - Q1 (Yes) (18)', 'hiPSC-CM Media Supplement - Albumin (28)', 'Disease Modelling - Genetic Disorders (18)', 'Coating for Replating - Matrigel (65)', 'Insulin Start Day - After 11 (7)', 'Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8)', 'Maturation Strategy - Metabolic (33)', 'hiPSC-CM Purification Duration (days) - 5 days (6)', 'hiPSC Backbone Media - Rare (19)', 'Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13)', 'Differentiation Purity Assessment - Flow Cytometry SIRPA+ (4)', 'Seeding Confluency 2D (%) - 85 to 89 (26)', 'Purification Protocol - Cell Sorting (7)', 'Journal - Circ Res (5)', 'Seeding Confluency (%) - 70 to 79 (11)', 'Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8)', 'Seeding Confluency 2D (%) - 70 to 79 (6)', 'Publication Year - 2019 (57)', 'Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13)', 'New Media for Maturation - F12 (7)', 'hiPSC-CM Media Supplement - bFGF (3)', 'Metabolic Component - Albumax (3)', 'Metabolic Component - Insulin-Transferrin-Selenium (3)']","['Publication Year - 2015 (19)', 'Electrophysiology Analysis Method - Optical Mapping (39)', 'Cell Line - iCell (47)', 'hiPSC-CM Media Supplement - iCell Maintenance Medium (41)', '3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24)', 'Journal - Nano Lett (3)', '3D Tissue Media - Iscove (5)', '3D Stromal Cell Source - hiPSC-CardiacF (8)', 'Publication Year - 2020 (51)', 'Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6)', 'Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8)', 'Coating for Replating - Gelatin (43)', 'Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7)', 'hiPSC-CM Maturation Media - iCell Maintenance (83)', 'Differentiation Purity Assessment - IHC a-actinin (8)', 'Maturation Strategy - Cell Alignment (59)', 'Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6)', 'Journal - Rare (104)', 'Seeding Confluency 3D (%) - 85 to 89 (12)', '2D Surface - Microelectrode Array (9)', 'hiPSC-CM Backbone Media - iCell Maintenance (86)', '3D Platform - Nanotechnology (3)', '3D Tissue Media - iCell Maintenance (12)', 'Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11)', 'Publication Year - 2019 (57)', 'Publication Year - Post 2020 (122)', 'Sacromere or Cellular Alignment Analysis - Yes (72)', '3D Tissue Media - Commercial Kit (21)', 'Maturation Strategy - Tension (64)', 'Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9)', '3D Platform - Fibronectin (3)']"
